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Abstract 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown aetiology.  Both 
genetic and environmental factors are known to contribute to disease development.  
Pathogenesis involves the production of autoantibodies, and the formation of immune 
complexes, leading to inflammation and destruction of autologous tissue.  SLE is a 
heterogeneous disease both longitudinally and between affected individuals, and is 
characterised by periods of exacerbation, known as flares, and periods of remission.  The 
ubiquitous human herpes viruses, cytomegalovirus (HCMV), and Epstein-Barr virus (EBV) 
have been associated with disease by a variety of mechanisms.    
Data compiled here suggests SLE patients have elevated IgG responses to HCMV and EBV, 
but unlike healthy controls these responses do not accumulate with age.  No association has 
been found between the carriage of these viruses, or the magnitude of response against these 
viruses, and any clinical measurements of disease activity.  EBV load is 5.4 times higher in 
SLE patients than controls. Azathioprine treatment is associated with a 4.4 fold rise in EBV 
load, no other drugs show associations with EBV load.  Among SLE patients EBV load is 
inversely correlated with CD8+ T-cell IFN responses, suggesting impaired T-cell responses 
are the cause of elevated load.  HCMV seropositivity is associated with a 7-year delay in 
development of disease among SLE patients, and a reduction in plasma IFN concentration. 
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SLE  
Systemic Lupus Erythematosus (SLE) is a heterogenous autoimmune disease with unknown 
aetiology.  As with other autoimmune diseases, pathogenesis is driven by immune targeting of 
autologous tissue.  Disease activity and severity vary, both between individuals and 
longitudinally.   Patients experience periods of activation, know as flares, and periods of 
remission.  Despite advances in treatment the mortality rate of SLE patients remains up to 
three times higher than matched controls [1].  A European study of 1000 patients from 1990 
to 2000 showed a 10-year survival of 90% [2], a huge improvement on the 5-year survival 
rate of 69% reported for 1949 to 1960 [3].  However, this reduction may also be due to 
changing criteria for SLE diagnosis[4].  SLE patients show a bimodal pattern of mortality.  In 
individuals diagnosed less than 5 years ago, the primary causes are sepsis and disease activity.  
In those diagnosed over 5 years ago the main cause of mortality is atherosclerosis and 
associated cardiovascular disease[5]. 
 
SLE is a heterogenous disease in terms of symptoms and severity, both in cross section and 
longitudinally.  This heterogeneity makes diagnosis a challenge, patients diagnosed since 
2000 exhibited the earliest symptoms 9 months before diagnosis.  Significant progress has 
been made in the time between onset of symptoms and diagnosis, which has improved from 
an average of 59 months in patients diagnosed before 1980 [6].  Because of this discrepancy, 
only the year, not the month or day, the patient was diagnosed is considered relevant in 
calculating disease duration.  Diagnosis is based on a patient fulfilling a number of 
immunological and clinical features, and the ruling out of other conditions, which can mimic 
symptoms.  Any organ and multiple organ systems can be involved.  Typical symptoms can 
 3  
include rash, fatigue, arthritis and arthralgia.  More severe cases can include nephritis and 
neurological symptoms [5]. 
Epidemiology 
The prevalence of SLE varies between populations.  In the US and Europe, incidence varies 
form 1 to 7.6 per 100,000 per year [7]. Prevalence has been reported to be as high as 
206/100000 in Afro-Caribbean females [8].  Prevalence and severity generally are lower 
among patients of European descent, and greatest among African Americans and Afro-
Caribbeans [9].  Prevalence and incidence depend on the method used to assess disease, and 
the method used to collect data.  Community based studies give different rates to hospital 
based studies, as hospital based studies are less likely to identify those with very mild disease 
activity. 
 
Risk factors 
Both genetic and environmental risk factors play a role in aetiology, as indicated by 
concordance rates of 25% in monozygotic twins and 2% in dizygotic twins [5].  
Autoantibodies responsible for pathogenesis in SLE are also found in healthy people.  It is not 
known why some individuals with these autoantibodies develop autoimmune disease and 
others do not.  It is likely that a number of factors contribute, and that when a threshold 
number of factors have accumulated, autoimmunity becomes clinically relevant.  
  
Environmental factors are also thought to contribute to SLE pathogenesis.  Concordance rates 
indicate that genetics alone cannot be responsible for disease development.   
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Genetics 
HLA 
The first genetic association found with SLE was in the genes encoding the Human Leukocyte  
antigens (HLA).  HLA molecules are the molecules used by cells to present peptides to T-
cells for immune surveillance.  They present to the immune system peptides within the cell 
and from the extracellular environment.  T-cells can only recognise peptide in the context of 
MHC molecules, unlike B-cells and antibodies, which are capable of recognising free peptide.  
HLA molecules are divided into two sub-types, HLA class I is ubiquitously expressed on all 
nucleated cells and presents a selection of intracellular peptides to CD8+ T-cells.  There are 
three different types of HLA I; HLA-A, HLA-B and HLA-C.  The maternal and paternal 
allele of each of these three are presented on the surface of all nucleated cells, therefore there 
are up to 6 types of HLA class I molecule on the surface of a cell, each presenting 
intracellular peptides to circulating CD8+ T-cells.  If a cell is infected with a virus, viral 
peptides are presented to the speciﬁc CD8+ T-cell, which will then kill the infected cell.  The 
second type of MHC molecule; HLA II molecules, are found only on specialised immune cell 
types such as B-cells and dendritic cells. These cells are professional antigen presenting cells 
or APC.  APCs take up exogenous antigen, both self and foreign, process it, and present via 
HLA II to CD4+ T-cells.  HLA class II molecules, present these extracellular peptides to 
CD4+ T-cells.  The HLA class II family is also comprised of three types; HLA-DR, HLA-DP 
and HLA-DQ.  HLA molecules, of classes I, and II, are hugely variable in their composition 
and ability to bind peptides.  Peptides are said to be ‘HLA restricted’ if they only bind to one 
allele of HLA molecule.  Both HLA class I, and HLA class II genes have been shown to be 
associated with SLE.  Certain HLA types are more common among SLE patients than 
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controls, in particular HLA-DRB1*0301 and HLA-DRB1*1501 and HLA-DQA1*0501-
HLA-DQB1*0201  [10]. 
Certain HLA types have also been associated with specific autoantibodies [11].  For example, 
patients carrying HLA DRB1*0402 are more likely to produce anti-cardiolipin antibodies, 
than other SLE patients.  These associations between HLA type and SLE are indicative of T-
cell involvement in development of pathogenesis. 
 
Complement deficiencies 
SLE is a disease in which the deposition, and accumulation of immune complexes leads to 
inflammation and damage.  As such, any genetic abnormality that impairs the clearance of 
immune complexes can predispose to SLE.  This is particularly true with the early 
complement proteins, which are necessary to start the complement cascade, which allows 
complex clearance. Mis-sense mutations in the first complement protein common to all three 
types of cascade, C3, almost invariably lead to SLE [12]. 
 
Sex 
In common with other autoimmune diseases SLE shows a strong sex bias; prevalence is 10 
times higher in females than males.  Among autoimmune disease, only Sjorgen’s syndrome 
shows a stronger female bias.  This sex bias is strongest during a childbearing years; juvenile 
SLE has a female to male ratio of 5.6: 1, and male patients are on average younger than 
female [13].   
 
It has been suggested that the different susceptibility of males and females is due to the 
number of X chromosomes an individual carries.  Individuals with Klienfelter’s syndrome, 
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with the karyotype 47 XXY, appear to be at similar risk of developing SLE as 46 XX females 
[14].  DNA methylation of the inactive X-chromosome, allowing TLR activation may be 
involved in the increased risk.  Female sex bias amongst SLE patients is strongest during the 
years in which females are fertile, leading to suggestions of an association with female 
hormones, such as oestrogen [15].  
 
Environmental influences 
UV light 
Among the most widely studied environmental influences in the development of SLE is 
ultraviolet (UV) light.  SLE flares are often preceded by sun exposure, amongst SLE patients 
living north of the arctic circle, flares are least common in January [16].  Furthermore, a 
photosensitive rash is amongst the American College of Rheumatology (ACR) criteria for 
defining SLE.  Experimentally it has been shown that UVA and UVB exposure triggers skin 
lesions consistent with SLE disease, and the use of UVA and UVB sunscreens has a 
protective effect [17, 18]. Furthermore, use of a tanning bed by a previously healthy 
individual was linked to the development of SLE [19]. 
SLE-prone mice are more susceptible to DNA damage by UVA than non-SLE-prone mice 
[20], and male BXSB mice are susceptible to premature death on UV exposure [21]. 
Whole body UV irradiation of NZLB/W F1 mice results in antibodies binding to epidermal 
cell nuclei and the production of anti-DNA/DNA immune complexes [22].  It is possible that 
UV light is exacerbating disease by inhibiting DNA methylation.  UV radiation de-methylates 
CD4+ T-cell DNA causing autoreactivity and/via LFA-1 overexpression [23].  It is also 
possible that UV exposure increases apoptosis.  UV irradiation of keratinocytes from SLE 
patients in-vitro increased the production of SLE associated antigens in apoptotic blebs [24]. 
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Infectious agents 
Another widely studied environmental influence is the herpes virus Epstein-Barr virus (EBV), 
which is more commonly found in SLE patients than healthy individuals [25].  This will be 
discussed in more detail in the relevant sections. 
HRT 
Risk of moderate flare is increased 1.34 times in menopausal women with lupus receiving 
hormone replacement therapy containing conjugated oestrogens and progesterone [26].  
However, there was no effect on the frequency of severe flares in the 12 moth period studied. 
Drug induced SLE 
Some drugs have been implicated in the development of lupus-like autoimmunity.  
Procainamide and hydralazine have been associated with the development of a Lupus-like 
syndrome.  Patients presenting with this condition usually have skin and joint involvement.  
Neurological or renal involvement is rare [Dubois 6
th
 edt 2002;885-916] 
 
Pathogenesis 
SLE is the result of type III hypersensitivity, in which antibody complexes are inappropriately 
formed and inefficiently cleared.  In SLE antibodies are produced against a large range of 
nuclear and cytoplasmic antigens.  Antibody complexes are deposited in tissues, causing 
inflammation and tissue damage.  Some of these antigens are targeted in other autoimmune 
diseases, whereas others are considered to be specific for SLE, such as antibodies against 
double stranded DNA (dsDNA).  Patients frequently have multiple auto-antibody specificities 
which accumulate over time, both before and after diagnosis [27]. 
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Clinical SLE is often preceded by a period of benign autoimmunity in which autoantibodies 
are present but the threshold for pathogenesis has not been reached.  Autoantibodies are 
detectable for years before disease development and are also detectable in individuals who 
never go on to develop an autoimmune disease.  The production of autoantibodies can 
precede the identification of disease by years.  In a prospective study of US military 
personnel, of 115 individuals who went on to develop SLE, 88% had at least one 
autoantibody present before diagnosis.  Autoantibodies were detected up to 9.4 years before 
diagnosis, with a mean time of 3.3 years.  These times are thought to be underestimates, as 
many of the first serum samples available for these individuals were already positive [27].  A 
later study of SLE patients in Sweden found that autoantibodies were detectable an average of 
5.6 years before onset of symptoms, and 8.7 years before diagnosis [28].  This study also 
revealed that there are difference in the times between the appearance of certain 
autoantibodies and the development of disease.  Anti-Ro and anti-La antibodies show the 
longest interval between detection and disease of 3.68± 0.34 and 3.61 ± 0.38 respectively.  
Anti-snRNP antibodies have an average interval of just 0.8 ± 0.32 years. It is thought that 
autoantibody specificities accumulate in SLE patients both before and after diagnosis [27], 
possibly initiating with just one specificity, then slowly diversifying.  
 
Humoral Abnormalities 
SLE patients, along with abnormal cellular immune function, have altered humoral responses.  
They have altered serum concentrations, and altered production capacity of a number of 
important cytokines.  Cytokines are soluble mediators of immune function, produced by 
immune cells, acting in an autocrine or paracrine manner.  
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IFN 
IFN is one of the most studied cytokines in SLE patients; it has been shown to be important 
in mouse models and in humans.  B6/lpr mice, deficient in IFN receptor, show improvement 
in clinical disease.  Also, between 20% and 80% of patients treated with IFN develop 
autoantibodies and some also develop clinical autoimmune diseases, including SLE.  IFN is 
a type I interferon.  The type I interferons (IFN-I) are a cytokine family comprised of 13 
different isoforms of IFN, along with IFN, IFNε, IFN and IFNω.  IFN can be produced 
by all leukocytes but is mainly produced by plasmacytoid dendritic cells (pDC), which 
comprise 0.2-0.6% of leukocytes.  It is produced in response to hypomethylated CpG DNA 
(Dubois, edt.4 p210) and immune complexes (Dubois, edt4  p27,30-32), via these molecules 
binding to Toll-like Receptor (TLR) 9.   IFN acts via the Jak/STAT1 pathway to modulate 
the responses of target cells causing the maturation of dendritic cells (Dubois, edt4 p65). It 
also leads to monocytes maturation, increasing their antigen presenting ability (Dubois, edt4 
p38), and causes increased NK and T-cell mediated cytotoxicity (Dubois, edt4 p78-80).  IFN 
also signals directly to CD8+ T-cells, acting as a third signal in combination with TCR and 
CD28 signalling.  The addition of the third signal from IFN increases proliferative ability, 
IFN production and cytolytic capacity [29]. 
 
SLE patients have up-regulated expression of a set of genes known as the IFN signature, 
which includes PRKR, IFIT1, LY6E, OAS1, IDG15, MX1 and IFI44 [30, 31]. 
 
SLE patients with the worst disease activity have higher serum IFN than those with milder 
disease and controls. IFN serum concentration in SLE patients correlates with anti-dsDNA 
 10  
antibody titre and complement activation; However, SLE patients in general do not have 
higher serum IFN.  Seemingly in contradiction to these findings, the pDC of SLE patients 
have impaired ability to produce IFN on direct, pDC specific, TLR-9 ligation.  One in three 
SLE patients are unable to produce any IFN with this type of stimulation.  It is thought that 
the pDCs in SLE patients have become exhausted through overstimulation.  Repeated 
stimulation of TLR-9 in healthy pDCs leads to exhaustion of IFN production, which is 
reversible after 24 hours without stimulation.  The PBMCs in SLE patients in this study had 
up-regulated IFN-inducible genes, suggesting that they had been exposed to IFN but the 
pDCs were unable to produce any more, due to overstimulation.  The same study also showed 
that the level of immune complexes in SLE patient sera, correlated with IFN production by 
healthy donor PBMC in co-culture.  Furthermore, those patients whose sera caused large 
amounts of IFN production from healthy PBMC were the same patients whose own pDC 
appeared to be exhausted [32]. 
 
Despite the many reports of up-regulation of the IFN signature in SLE, and its association 
with disease activity, it appears it is not a good marker of longitudinal changes in SLE disease 
activity, so is of limited use clinically [31]. 
 
IFN 
Interferon  (IFN) is the sole member of the type II interferon family.  It is produced 
primarily by NK cells but is also produced by Th1 CD4
+
 cells, and CD8+ T-cells.  It is a pro-
inflammatory cytokine, which activates monocytes and induces TNF production, via STAT1 
signalling (Dubois 4
th
 edition 179).  In mouse models of SLE, IFN is crucial for the 
development of nephritis (Dubois 4
th
 edition 168 185) and for the production of pathogenic 
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IgGIIa antibodies (Dubois 4
th
 edition 168-170 180-183).  Deletion of the IFN receptor gene 
in NZB/W F1 and MRL/lpr mice increased survival and improved renal disease.  Reduction 
of serum IFN using the IFNR fusion protein in MLR/lpr mice resulted in clinical benefit.  A 
role for IFN in human SLE is not as clear, expression level of CXCL9 mRNA; a gene 
product induced by IFN is not upregulated in SLE patients.  However, it has been shown that 
on stimulation with anti-CD3 and anti-CD28 antibodies, PBMC from SLE patients produce 
significantly more IFN [33] 
 
Cellular abnormalities 
The purpose of the immune system is to protect the body from damaging pathogens, and to 
destroy cancerous cells.  It is important however, that the immune system does not damage 
self-tissue, so it must be able to distinguish between self and foreign antigens.  T-cells are 
educated in discriminating between self and non-self in the thymus, after emigrating from the 
bone marrow.  In the thymus new T-cells encounter a range of self-antigens.  Those that react 
too strongly to self-antigens are deleted, a process known as central tolerance.  It was thought 
that this was the only mechanism the body used to avoid autoimmune attack, however self-
reactive B-cells and T-cells have been found circulating in the peripheral blood of healthy 
controls and in various autoimmune conditions [34].  In healthy control these cells are 
anergic, and do not cause autoimmune damage.  In autoimmune conditions the peripheral 
tolerance required to keep these cells anergic has been overcome, and many cell types 
contribute to autoimmune damage.  Here, the cellular abnormalities, which may be 
contributing to loss of tolerance in SLE patients, will be discussed. 
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Peripheral Blood Mononuclear cells (PBMC) abnormalities 
Cytopenias including thrombocytopenia, anaemia and lymphopenia are common in patients 
with SLE.  Both autoimmune destruction, and disease treatment are thought to be responsible. 
 
B-cell abnormalities 
As B-cells are responsible for the production of pathogenic autoantibodies in SLE, it is 
important to consider any alterations of frequency or function of this type of cell.  B-cells 
comprise around 5-15% of circulating lymphocytes.  They are derived from haemopoietic 
stem cells, via pro-B cells and pre-B-cells in bone marrow.  B-cells are defined by the 
presence of surface immunoglobulin, of which there are five types.  Most peripheral B-cells 
bear immunoglobulin M and D (IgM and IgD).  A smaller percentage bears IgG, IgE and IgA 
immunoglobulins.  On any particular B-cell, all immunoglobulins are identical, and define the 
cell’s specificity.  On encountering the antigen specific for it’s immunoglobulin, the B-cell 
undergoes maturation and develops into a long-lived memory cell, or an antibody producing 
plasma cell.  Memory B-cells in SLE are hyper responsive to stimulation, possibly as a result 
of the altered cytokine profile, and therefore may be more likely to overcome tolerance [35].   
The contribution of B-cells to SLE pathogenesis can be broadly grouped into two categories; 
firstly, by the production of pathogenic, immune complex forming autoantibodies, discussed 
earlier; and secondly by their ability to modulate the activity of other immune cells such as T-
cells, by antigen presentation, or the production of immunoregulatory cytokines and 
chemokines. 
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T-Cell abnormalities 
T-cells are a group of lymphocytes defined by their expression of the T-cell antigen receptor 
(TCR).  T-cells, like B-cells, are also derived from HSCs but mature in the thymus.  There are 
two types of TCR, both disulphide bond linked heterodimers, called  TCR and  TCR, in 
reference to their polypeptide chain components.   T-cells are by far the more common cell 
type, comprising 90-95% of peripheral T-cell.  TCRs are found in association with the CD3 
complex, and a set of 5 other polypeptides, which combined make up the TCR-CD3 complex.  
This complex recognises antigen presented by APCs expressing MHC class I or II, and 
transmits the signal intracellularly.   T-cells are furtherer categorised by their expression of 
CD4 or CD8 molecules.  Most  T-cells express one or the other of these molecules, but a 
small proportion express neither or both.  CD4+ T-cells recognise peptide presented my MHC 
class II molecules, CD8+ T-cells recognise peptide presented by MHC class I molecules.  
CD8+ T-cells are mostly cytotoxic, and kill infected cells or tumour cells, and are often 
referred to as Tc.  CD4+ T-cells generally function by recognising pathogens and stimulating 
other cell types to destroy the infected cells, and are therefore often known as helper T-cells 
or Th.  T-cells are further subdivided by the cytokines expressed, and by their activatory or 
inhibitory subtype. 
T-cells have been implicated in the pathogenesis of SLE.   Firstly, the selective deletion of T-
cells in SLE prone mouse models abrogates disease, and T-cell deficient mice cannot develop 
SLE.  In humans, SLE is strongly linked to HLA-type, indicating antigen presentation has a 
role in disease induction.  Furthermore, plasma cells producing pathogenic autoantibodies 
show evidence of having had assistance from T-cells, producing large quantities of high 
avidity IgG antibodies that have undergone somatic hypermutation, a process dependant on T-
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cell help.  Finally, a number of groups have detected autoreactive T-cells in the peripheral 
blood of SLE patients [36].  As with autoreactive B-cells, these are also found in healthy 
controls.  However, auto reactive. T-cells in SLE patients can support antibody production by 
B-cells ex-vivo.  T-cells have also been found infiltrated into SLE kidneys in patients with 
lupus nephritis [37]. 
SLE patients have increased CD4:CD8 ratio and decreased HLA-DR expression on treatment 
with steroids or cyclosporine [38][39].  SLE patient CD3+ CD8+ and CD3+ CD4+ cells are 
more susceptible to apoptosis than cells of healthy individuals.  When healthy PBMC were 
cultured with SLE serum rather than healthy control serum, they also underwent more 
apoptosis, an effect which was significantly reduced by the addition of an anti-IL-10 antibody 
[39]. 
 
SLE patients have reduced numbers of T-cell receptor excision circles (TREC) [40].  TRECs 
are recognised as markers of thymic output, cells bearing this intracellular marker are recent 
thymic emigrants.  Another study found reduced TREC levels in patients with active disease, 
but not inactive disease, suggesting SLE disease activity modulated TREC levels [41]. 
 
Th17 
SLE patients have increased levels of IL-17 in plasma and serum [42].  This cytokine, 
produced by Th17 cells, is proinflammatory and recruits and activates neutrophils.  It also 
works with BAFF (which is also up-regulated in SLE) to promote the survival of B-cells and 
their differentiation into plasma cells.  SLE patients also have more CD4+ cells capable of 
producing IL-17 (Th17), despite having similar percentages of IFN producing cells to 
healthy controls.  IFN usually suppresses the differentiation of Th17 cells, so it is suggested 
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that the balance between Th1 IFN producing cells and TH17 IL17 producing cells is 
dysregulated in SLE.  
 
CD8+ 
SLE patients have been shown to have a higher proportion of CD8+ CD28- T-cells [43].  This 
T-cell type is thought to be suppressive, both by cell/cell contact and via cytokine production.  
One of the cytokines they produce is IL10. Cells of this subset in SLE are not capable of 
producing as much IL10 as healthy controls [44, 45].  Reduction in CD28 expression is also a 
marker of cells having undergone stimulation.  CD28 is downregulated on stimulation.  
Higher frequencies of cells which have downregulated this marker, indicates more highly 
stimulated T-cell pool.   
 
T-reg 
T-regulatory cells (T-reg) are a group of T-cells commonly characterised by surface 
expression of CD4
+
 CD25
high
 CD127
-,
 and intracellular expression of the transcription factor 
FoxP3
+
.  Unlike other T-cells, they are suppressive, downregulating the inflammatory effects 
of other T-cells, and play a vital role in maintaining peripheral tolerance.  It is therefore 
possible that in autoimmune conditions, T-reg function may be impaired, or frequency 
reduced.  Studies reporting the frequencies of T-reg in SLE give confliction results, some 
reporting reduced frequencies, others reporting no alterations [46].  Inconsistent methods of 
defining phenotype, and the heterogenous nature of SLE disease and disease activity scoring 
techniques may account for these inconsistencies.  Some studies rely only on the surface 
phenotype to define a T-reg, without considering the expression of Fox-P3.  Examining 
functional capacity of T-regs in SLE patients has also given conflicting information, with 
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some studies describing altered suppressive capacity in SLE relative to healthy controls and 
other describing no such difference.  In-vivo studies have shown that Fox-P3 levels are not 
consistent within lymphocytes, so a cell isolated based on its expression of Fox-P3 directly 
ex-vivo may not be expressing Fox-P3 and may not be acting as a regulatory cell type in 
functional assays [46].  Other suppressive T-cell populations may be involved in SLE 
pathogenisis, for example NKG2D+ CD4+ T-cells are inversely correlated with disease 
activity[47]. 
 
 
NK cell abnormalities 
SLE patients also have abnormalities in the innate immune compartment.  These 
abnormalities contribute to disease by altering antigen presentation or abnormal signalling to 
the adaptive immune system.   
 
Natural killer cells are innate immune cells, derived from hematopoietic stem cells.  They 
comprise up to 15% of peripheral blood lymphocytes.  They are identified by their surface 
expression of CD16, which is a Fc III receptor, and CD56, an adhesion molecule of the Ig 
superfamily.  NK cells are activated by recognition of infected cells or tumour cells, and kill 
their targets using perforin and granzyme.  Activation of NK cells is dependant on the balance 
of activatory and inhibitory signals they receive. 
SLE patients have fewer than normal NK cells, both in terms of absolute numbers and as a 
percentage of the total. This was more significant in patients with lupus nephritis or 
thrombocytopenia.  NK cells isolated from SLE patients have reduced cytotoxic capacity, due 
to a down-regulation of perforin and granzyme.  Differentiation of HSCs into NKs is also 
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defective [48].  NK cells, along with a subset of T-cells, express killer immunoglobulin-like 
receptors (KIRs).  These molecules bind to MHC class I molecules, and modulate NK 
activation.  KIR binding can cause or suppress NK activation, depending on whether the KIR 
is activatory or inhibitory.  Inhibitory KIRs bind MHCI presenting autologous peptide 
prevents NK activation, and therefore stops NKs killing healthy cells.  MHC I is down-
regulated by virus infection of cells, to prevent T-cell recognition of the infection.  This 
leaves the cell vulnerable to NK-mediated killing, as the inhibitory KIRS are not stimulated.  
KIRs are highly polymorphic and have numerous alleles.  SLE patients are more likely to 
have two or more activatory KIR genes than healthy controls.  Frequency of activatory KIR 
genes is also higher in other autoimmune conditions [49] 
 
 
Clinical evaluation and treatment 
Evaluation 
As SLE is such a heterogenous disease it is vital to have a standardised method for the 
assessment of disease severity.  Standardisation allows comparisons to be made between 
affected individuals, and longitudinally.  This is an important consideration when assessing 
the efficacy of treatment and for the comparison of patients at different centres.  There are 
two parameters that can be examined in assessing disease in SLE patients: Disease activity 
and damage.  Both disease activity and damage are difficult to score directly; due to the 
multisystem nature of the disease, even within a given system, disease can be very 
heterogenous. A number of indirect scoring systems have been developed to asses disease 
severity, not all of which have been validated.  Disease activity is reversible, and the score 
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reflects the severity of disease on the day of assessment.  Damage is not reversible, and is 
cumulative, reflecting the scarring that has occurred as a result of disease activity.  
One of the systems used to grade disease activity is the BILAG scoring system.  This is a 
physician completed system, developed in 1984 by the British Isles Lupus Assessment Group, 
since when, it has undergone numerous modifications.  One of these modifications was 
validated in 1986 and became known as the ‘Classic BILAG’.  The scoring system is split 
into eight different systems, containing 86 items for assessment.  The eight systems are: 
general, mucocutaneous, neurology, musculoskeletal, cardiorespiratory, vasculitis, renal and 
haematology.  Each of these systems is given a grade to reflect the severity of disease in that 
system in the month of assessment compared to the previous month.  An A grade reflects the 
most severe activity, progressing down to D grade indicating inactive disease, and E grade 
showing the system has never been involved.  This method of assessing disease activity will 
be used throughout this work. 
Disease damage is assessed using The Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology Damage Index (SDI).  This is a measure of 
chronic damage.  It is a physician completed scoring system giving a numerical value of 
between 0 and 46, which reflects the level of accumulated damage.  The system includes 41 
items, covering 12 systems, with each item being weighed based on severity.  Unlike 
SLEDAI scores can not reduce over time, but increases to reflect damage accumulation [50]. 
 
Markers of disease activity used clinically include the complement components 3 and 4 (C3, 
C4.  The complement system is a collection of membrane bound and soluble proteins which, 
via sequential activation know as the complement cascade, aid in the defence against 
pathogens and mediate the function of other immune cells [12].  There are three known 
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complement cascades; the classic, alternative and lectin pathways.  C3 activation is necessary 
for the activation of all three complement cascades.  Individuals homozygous for a C4 null 
allele are likely to develop SLE; C4 deficiency is linked to other autoimmune conditions.  
This feature of C4 is shared with all members of the classical pathway including C3 [51] [12].  
As C3 and C4 are required for complement activation, excessive activation of the immune 
system via autoantibody binding can cause exhaustion of the supply of these proteins.  
Therefore, low or declining levels of C3 and C4 are indicative of worsening activity, and are 
one of the clinical parameter used in disease monitoring. 
C- reactive protein (CRP), named due to its ability to precipitate the C-fraction of the cell wall 
of Streptococcus pneumoniae, is used as a marker of systemic inflammation [52].  Serum 
levels rise non-specifically in response to tissue injury and infection.  CRP binding, to 
antigens containing phosphocholine, triggers the classical complement pathway via 
opsonisation and the recruitment of C1q.  It is measured routinely in SLE and a number of 
other conditions as a marker of disease activity [53]. 
The presence of antibodies capable of binding dsDNA is specific for SLE, as opposed to other 
autoantibodies, which are found in other autoimmune conditions.  Their identification in 
tissues of patients with SLE mediated nephritis has lead to the suggestion that they are 
pathogenic, also titre correlates well with disease activity, so is widely used as a biomarker 
[54].  Furthermore they are found in up to 95% of untreated SLE patients[54]. Lymphocyte 
counts are also recorded as part of routine disease monitoring.  Both SLE disease and its 
immunosuppressive treatment cause lymphocytosis.   
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Treatment 
SLE treatment, like disease itself, is heterologous.  It is generally treated using a variety of 
immunosuppressive agents, steroids and anti-malarial drugs.  One of the most commonly 
prescribed is prednisilone, a steroidal anti-inflammatory drug given varying doses, depending 
on severity of symptoms.    
The anti-malarial drug hydroxycholoquinne is also widely used, particularly for skin and joint 
involvement, and fatigue.  It is the only drug that has been shown to inhibit the accumulation 
of SLE induced damage [55].  Its mechanism of action remains unclear.  The 
immunosupressants azathioprine and cyclosporine are also widely utilised, often as 
alternatives to corticosteroids, in order to avoid the side effects associated with corticosteroid 
usage [56].  Azathioprine is a purine analogue, used in solid organ transplants, haematological 
malignancies and inflammatory bowel disease in addition to SLE and other rhematological 
diseases.  It is thought to function by its incorporation into replicating DNA[57].  
Azathioprine also functions by inhibiting CD28 signalling, causing CD28 ligation to result in 
apoptosis rather than co-simulation [58].  Cyclosporine A selectively inhibits T-cell responses 
by inhibiting the secretion of a number of cytokines including IGN [59].  Biological 
treatments for SLE include rituximab, and anti-CD20 monoclonal antibody, which binds the 
CD20 molecule, found on most stages of B-cell differentiation, depleting B-cell numbers. It 
has beneficial effects on CD3, CD4 and dsDNA titres [60].  In severe refractory SLE, 
autologous stem cell transplant has been used, resulting in around 30% complete response but 
11% 1 year transplant related mortality [61].  Another study of 17 SLE patients showed 7 year 
overall survival of 82.4 ± 9.2 years [62]. 
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HCMV 
History and Discovery 
Human Cytomegalovirus (HCMV) was first identified as a result of the pathogenic 
consequences of congenital infections.  The presence of features, now know to be a result of 
Cytomegalovirus infection, were noted in premature foetuses and stillborn infants in the late 
19
th
 and early 20
th
 century (Fields Virology edt 4 , 147 and 241 179).  They described an 
intranuclear inclusion surrounded by a clear zone in multiple organs of infants thought to have 
died from other causes.  It was noted that these cellular features were similar to those 
produced by herpesviruses.  By 1926 it had been shown that the cytomegalic cells were due to 
a filtratable, heat-inactivated agent (Fields Virology edt 4, 71).  In 1953 Minder et al had 
shown, using electron microscopy, what appeared to be virus particles in the cytoplasm of 
cells with included nuclei (Fields Virology edt 4, 190).  HCMV was first isolated in the 1950s 
by three separate laboratories (Fields Virolgy edt 4, 244,260,302), allowing in-vitro study of 
the study of the virus. 
Phylogeny 
 HCMV is a member of the order Herpesvirales, a group containing 17 genera and 90 
different species, with host specificities encompassing the majority of vertebrate orders.  This 
wide spread amongst different classes of host suggests these viruses are of an ancient origin, 
and that the viruses has been evolving with their hosts over millions of years.  HCMV is one 
of eight Herpesviruses to infect humans, it is also known as human herpes virus 5, and is a 
member of the subfamily, betaherpesvirinae.  This category, it shares with and human herpes 
viruses 6 and 7 [63].   
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Structure 
All Herpesvirales share the same physical structures and use double-stranded DNA to carry 
their genetic information.  Their DNA is packaged in an icosahedral capsid, which is 
surrounded by a protein rich matrix called the tegument.  A glycolipid membrane then 
encases the entire virus. 
 
Genetics 
At 235kbp, the genome of HCMV is one of the largest and most complex viral genomes.  It is 
linear in structure and is G+C rich.  One of the best studied viruses, AD169, reveals 208 non-
overlapping ORFs of greater than 80 codons.  However this virus is derived from a strain 
grown under conditions designed to reduce virulence for use as a live vaccine.  As such it has 
undergone 25 years of serial passage in-vitro, and has accumulated errors and modifications 
which distinguish it from clinical isolates [63]. 
 
 
Epidemiology and transmission 
Prevalence  
HCMV is a very common virus; it is found in 30-90% of the world’s population, prevalence 
is inversely correlated with socioeconomic status. It is more common in less developed 
countries.  In common with the infection protocol of all herpes viruses, infection is followed 
by lifelong carriage in the healthy host.  However, unlike some other herpes viruses, initial 
infection is usually asymptomatic, although it can cause a mononucleosis-like illness on 
occasion.  HCMV is thought to be responsible for 7% of infectious mononucleosis cases [64].  
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HCMV persists in the myeloid cell line, in monocytes, but may also be capable of infecting 
other cell lines in vitro [65] [66]. The virus is also thought to persist in CD34+ cells within the 
bone marrow [66] [67].In vitro culture of the virus is usually achieved in fibroblasts; other 
cell types are permissive but have limited ability to produce virus.   
 
 
As initial HCMV infection rarely has symptoms, it is difficult to determine at what age an 
individual acquired the virus.  The virus in normally acquired in infancy, when it is 
transmitted to neonates via breast milk. Unlike other human Herpesviruses, it can be 
transmitted in utero, via the placenta.  It can also be transmitted to the neonate during labour 
[68]. 
As the prevalence of the virus increases with the age of the population studied, it is clear that 
the virus can be acquired at any age.  Seroconversion rates also depend on the population 
studied, in particular, those who are in contact with young children have higher rates.  Virus 
can be transmitted in any body fluid; young children frequently shed the virus.  
Seroconversion rates among the parents of non-shedding children in the USA between 1986 
and 1989 were 3%, compared to parents of children who were shedding having a rate of 30%.  
Among the adult population in general, the annual seroconversion rate is 0.6%.  This figure is 
based on the results of a German study of 13160 female blood donors between 30 and 35, 
between 1992 and 2002 [69].  Prevalence in this study varied from around 30% among 18-20 
year olds to over 80% in those aged over 60.  HCMV infection was consistently more 
common in females than males at all ages, and peak of seroconversion rate was between 31 
and 35.  In Europe, seroconversion rates among pregnant women are between 0.7 and 4% [70]  
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Immunology 
Immune control in healthy people 
HMCV specific T-cells are identifiable at an average of 7 days after the identification of 
HCMV DNA in blood [71].  Phosphoprotein 65 (pp65) is a viral peptide recognised by the 
CD4+ T-cells of 63% of seropositive donors.  83% of seropositive donors have a CD8+ T-cell 
response against this antigen [72].  Anti-HCMV IgM appears on primary infection but can 
persist in some individuals.  IgG appears later.  IgG in individuals also expressing IgM, is 
usually of low avidity, indicative of more recant infection as the response has not undergone 
affinity maturation or somatic hypermutation. 
 
Immune evasion 
Lifelong persistence requires strict immune surveillance, co-ordinated between the humoral 
and cellular immune system, to stop reactivation.  Conversely, the virus needs to persist, so 
alters the immune response in order to do so.  A balance is struck, such that the virus persists 
at very low levels, without causing disease. 
Cytomegalovirus has evolved a number of methods of evading immune destruction.  It evades 
T-cell mediated immunity by downregulating surface expression of MHC-class II and MHC 
class I molecules, and expression of HLA-E [73].  HCMV infection of DCs results in 
impaired maturation and surface expression of MHCII [74].   The absence or reduction of 
MHC- class II  should make the virus susceptible to NK mediated killing ,as MHC-II engages 
inhibitory receptors on NK cells, and prevents activation.  However NK cell killing or 
tolerance depends on the balance of activatory or inhibitory signals it receives.  HCMV is also 
able to modulate the expression of the NKG2D ligands- ULBP1, ULBP2, ULBP3, ULBP4, 
ULBP5, ULBP6, MicA and MicB [75].  This set of molecules is expressed by infected or 
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damaged cells, to allow NK cell recognition via NKG2D, and ultimately, destruction of the 
cell.  HCMV can reduce the surface expression of this set of molecules, allowing it to go 
undetected by NK cells.  The virus normally achieves this by retaining the ligands 
intracellularly, often in the endoplasmic reticulum [75].   
 
Immune modulation 
HCMV infection has a major impact on the composition of peripheral lymphoid subsets in 
healthy carriers.  HCMV positive individuals have a significantly decreased ratio of CD4+ T-
cells to CD8+ T-cells, due to an increase in CD8+ LFA
hi
 and CD8+ LFA
hi
 CD45RA+ 
memory T-cells.  This is accompanied by a 40% reduction in naïve CD8+ T-cells.  A 
reduction in the proportion of naïve CD8+ T-cells is a normal consequence of aging; HCMV 
accelerates the changes HCMV positivity also increases the numbers of CD4+ effector 
memory cells [69].  HCMV may contribute to an ‘immune risk phenotype’ and an associated 
increased risk of morbidity and mortality with increasing age. 
HCMV infection is also associated with shortening of telomeres in T-cells, a characteristic 
caused by progressive shortening with each cell division and associated with immune 
senescence and increased morbidity [76]. 
 
Differentiation markers 
CD28 is a 44kDa homodimeric co-stimulatory molecule found on the surface of CD4+ and 
CD8+ T-cells.  CD28 ligation, in combination with specific antigen/MHC interaction with 
TCR, causes T-cell activation via recruitment of protein kinase cθ, allowing proliferation and 
cytokine secretion.  Its ligands are B7 family members, B7-1 and B7-2 (CD80 and CD86), 
which are expressed on antigen presenting cells.  CD80 is constitutively presented on APCs, 
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whereas CD86 expression is upregulated on activation of APCs.  CTLA-4 is a homologue of 
CD28, which has inhibitory activity.  It also binds CD80 and CD86 but with higher affinity. 
CMV infection is associated with the presence of higher frequencies of CD28- CD4+ and 
CD8+ T-cells [77]. 
 
CD27 is a 55kDa transmembrane glycoprotein receptor.  It is member of the TNF-receptor 
superfamily, and is a co-stimulatory molecule found on the majority of peripheral blood T-
cells, NK cells and on 33% of peripheral B-cells.  Its ligand, CD70 is expressed on activated 
B and T-cells.  CD27 stimulation is necessary for the survival and proliferation of low affinity 
T-cells, by reducing the necessary stimulation threshold [78].  It is up-regulated following 
antigen exposure.  CD27 is expressed at lower levels on CD4+ and CD8+ T-cells in HCMV 
positive individuals. 
CD57 is an 110kDa glycoprotein expressed on subsets of NK, B-cells and T-cells.  CMV 
positive individuals have significantly higher expression of CD57 on CD4+ T-cells [79].  It is 
commonly used as a marker of antigen experience. 
 
Pathology 
HCMV is able to reactivate and replicate in hosts with impaired immune control.  This occurs 
in the case of AIDS patients, those given immunosuppressant drugs, in utero and in those 
acquiring the virus from a HCMV positive organ without pre-existing anti-HCMV defences 
[80].  It has also been shown to reactivate in astronauts, possibly due to the stresses of space 
[81].  In general, in immunocompromised patients and pregnant women, primary infection is 
more severe than either a secondary infection or a reactivation of latent virus.  This may be 
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because the individual has not developed the immune response required to control the 
infection.   
 
Pathogenesis in utero 
Congenital HCMV infections occur when the mother experiences primary infection, 
secondary infection or reactivation of latent virus at any stage of gestation.  Such infections 
are capable of causing significant damage to the baby and can cause mental retardation and 
other developmental problems.  The risk of transmission to the foetus in primary maternal 
HCMV infection is 30.1% in the first trimester, rising to 72.2% in the last trimester.  
However, only 10% of newborns suffer severe symptoms, frequencies are higher among those 
infected early in pregnancy compared to those infected later [82].  Transmission via breast 
milk to low birth weight and premature infants can cause symptomatic infections.  
 
Pathogenesis immunocompromised adults 
HCMV reactivation and primary infection are also a significant cause of morbidity and 
mortality among patients undergoing solid organ or bone marrow transplants.  In the 1970s, 
96% of kidney transplant recipients experienced HCMV reactivation, resulting in significant 
morbidity [80].  By 2008, 56% of patients were experiencing at least 1 reactivation in the year 
following transplant, an improvement likely due to the increasing use of anti-viral prophylaxis 
[83].  The outcome is also linked to seropositivity of donor and recipient.  Morbidity is most 
severe if a HCMV seronegative individual receives a transplant from a seropositive 
individual, as the patient has no pre-existing immunity. 
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EBV 
History and discovery 
Epstein-Barr virus (EBV) was first identified by Tony Epstein and Yvonne Barr, by using 
electron microscopy to examine cell lines derived from Burkitt’s lymphoma (Fields edt 4 
124).  This type of tumour is endemic to equatorial Africa, and was studied and treated by 
Denis Burkitt in the 1950s.  Burkitt was first to note that the geographical distribution of this 
tumour suggested an infectious causative agent. EBV was the first virus to be associated with 
a tumour.  It was later found, unexpectedly, that this virus was common in all human 
populations, not just in equatorial Africa, and could therefore not be sufficient for tumour 
formation. 
 
Phylogeny 
Epstein-Barr virus (EBV) is a human -herpesvirus, it is present in over 90% of the adult 
population.  As with HCMV, prevalence is highest in populations with a lower socioeconomic 
status, and increases with age.  EBV is a lymphocryptovirus, a group defined by their ability 
to persist in the lymphocytes of seropositive hosts.  The lymphocryptoviruses of other species 
are EBV homologues, and are found in old and new world primates.  All are members of the 
-herpesviridae subfamily.  Of the human herpes viruses, EBV is most closely related to 
Karposi’s sarcoma herpes virus (KSHV), also a -herpesvirus which infects B-cells and shows 
similar replication mechanism to EBV [84]. 
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Structure and important components 
EBV and HCMV share a common structure, in which a double stranded linear DNA core is 
enclosed by the icosahedral capsid, and then surrounded by the tegument and the membrane.   
EBV contains a linear double stranded DNA genome, composed of 184-kbp. 
 
Epstein-Barr virus nuclear antigen-1 is the only antigen to be expressed in all EBV related 
malignancies.  It is a transcriptional regulator of latent replication and, essential for the 
maintenance of the viral episome within the host.  EBNA-1 specific CD4+ and CD8+ T-cells 
have been identified, despite earlier reports suggesting it was capable of evading T-cell 
responses [85].  Anti-EBNA-1 antibodies appear 3-4 weeks after infection, and are used as a 
marker of previous infection. 
EBV viral capsid antigen (VCA) is a structural protein expressed only during lytic infection 
[86].  Antibodies appear soon after infection and are maintained for the lifetime of the host.  
The presence of IgG and IgM antibodies against EBV VCA is used diagnostically. 
BALF-5 is an EBV encoded DNA polymerase. It encodes an early lytic cycle antigen[87].  
This gene is used for the identification of EBV genome in PBMC. 
 
In Vitro culture 
The ability of EBV to replicate in a specific cell type in-vitro is determined by the presence of 
the EBV receptor CR2.  This molecule is found on most B-cell types, but not on plasma cells.  
EBV has two forms of replication, lytic infection, and latent infection, which can be further 
categorised into Latency I, II, III and 0.  Each replication method involves the expression of 
different sets of genes. 
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Epidemiology and transmission 
Primary EBV infection usually occurs asymptomatically in infancy, and is acquired from the 
parent via saliva.  If infection is delayed until adolescence, it can result in a self-limiting 
condition called infectious mononucleosis in up to 25% of cases.  Infectious mononucleosis 
can also occur on infection of infants, but is rare.  Symptoms include lymphadenopathy, fever 
and malaise.  Symptoms are caused by T-cell activation, and cytokine production.  Infectious 
mononucleosis is characterised by lymphocytosis, in which up to 80% of circulating 
lymphocytes can be CD8+.  This expansion is antigen driven, and the majority of these cells 
are antigen specific.  With the decline of symptoms, the T-cell pool contracts [84].  Virus is 
then maintained in a latent state, at greatly reduced levels, for the lifetime of the host.  
Reactivation can occur in cases of immunosuppression.  Reactivation can also occur as a 
result of stress, as measured by serum cortisol and epinephrine concentrations.  More frequent 
reactivation occurs in those with the highest concentrations of these hormones [88].  
Reactivation also occurs in apparently healthy controls.  A small study of 14 healthy people 
found that 12 of them had at least one asymptomatic reactivation within a year.  Reactivation 
was associated with periods of significantly lower T-cell responses, as measured by IFN 
production in response to lymphoblastoid cell lines [89]. 
 
Virus generally transmitted via saliva, it is shed from epithelial cells in the oropharynx.  Virus 
is present in the saliva of most infected individuals [90].  Initial infection is also thought to 
occur in epithelial cells within the oropharynx.  This is followed by transmission to B-cells, 
causing B-cell expansion, which serves to increase the number of virus particles.  EBV can 
also be transmitted by sexual intercourse, as virus can be detected, although at low levels, in 
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cervical and semen samples, and viral isolates were more frequently identical amongst sexual 
partners than non-sexual contacts [90].  Risk of acquiring virus also increases with number of 
sexual partners [91] [92]. 
EBV seropositivity is less common in those with higher socioeconomic status; infection is 
associated with lower paternal education, and smoking [93] and in females. Seroprevalence is 
also higher amongst individuals with a larger number of sexual partners [90]. 
Immunology 
Control of EBV is primarily mediated by T-cells; both CD4+ and CD8+ cells are involved.  
The magnitude of T-cell response is generally smaller than anti-HCMV response.  EBV 
specific cells have effector phenotype, but are not as highly differentiated and HCMV specific 
T-cells [84].  Frequency of anti-EBV T-cells is greatest during the recovery phase form 
primary infection, the increase in T-cell frequency correlated with the rate of reduction of 
EBV load [94]. 
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Associations between SLE and HCMV 
IgG 
SLE patients have been shown to have higher titres of anti-HCMV IgG than both healthy 
controls and patients with other autoimmune conditions.  The higher antibody titre appears to 
be specific for HCMV, as higher titre antibodies are not found against Hepatitis-B virus or 
Epstein-Barr virus.  It has also been shown that SLE patients have a higher prevalence of 
antibodies against pp65 by pp65 specific ELISA, and titres around double those of normal 
individuals.  This finding was specific for SLE patients, as increased titres were not found in 
patients with other autoimmune diseases [87].  In healthy individuals HCMV seropositivity is 
associated with increased titres of autoantibodies, against RNP, Sm and U1-70k (p<0.0001, 
p=0.002 and p<0.0001 respectively) despite total IgG titres being similar.  U1-70k is one of 
the snRNP proteins, and is often the first, of this group against which autoantibodies are 
generated. Another study shows that U1-RNP is more frequently targeted in SLE patients 
with high anti-HCMV titres than those with low anti-HCMV titres [95].  Other sn RNP 
specificities then accumulate over time, and are found in 30% of SLE patients.  If responses to 
this antigen are more common in HCMV positive individuals, those with genetic 
predisposition and HCMV seropositivity may be more likely to develop SLE than HCMV 
negative people. 
Anti-RNP responses are also more common in HCMV positive SLE patients than HCMV 
negative SLE patients [96]. MRL/mpj autoimmune prone mice, when vaccinated with an 
adenovirus vector encoding HCMV gB developed autoantibodies against U1-70k. Three other 
non-autoimmune mouse strains also develop autoantibodies against U1-70kDa, suggesting 
this is not just an autoimmune phenomenon.  All mouse strains also developed anti-RNP and 
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anti-sm antibodies on vaccination with gB, whereas those vaccinated with PBS or HeLa 
extract did not [97].  However, 4 years later the same group vaccinated HCMV negative 
healthy humans with recombinant soluble gB, and found no difference in pre and post-
vaccination U1-70kDa responses.  Furthermore no individual vaccinated had more than a 2-
fold increase in anti-Sm and anti-RNP antibodies with vaccination.  The purpose of this study 
however, was to assess the safety of a potential HCMV gB based vaccine, not to assess the 
potential of HCMV to cause autoimmunity.  It does indicate that gB responses alone are 
insufficient to cause autoimmunity, and are probably insufficient to induce the production of 
autoantibodies.  Instead, it is likely that genetic predisposition plays a role in disease 
development.  A/J and B6 mice were immunised with an adenovirus vector expressing gB.  
A/J mice developed responses to U1-70kDa rapidly, and also accumulated deposits of IgG in 
their kidneys.  B6 mice developed neither feature.  A/J mice also exhibited a divergence of 
their antibody responses to other closely associated snRNP antigens, as is seen in the 
development of human SLE [98]. GB and U1-70kDa share some structural homology, 
meaning this generation of autoantibodies could be as a result of molecular mimicry.  This 
concept, first suggested by Damian et al in 1964 [97], suggests than antibodies can bind 
different antigens, with very similar structures, and that on encountering ether antigen, the 
host develops a response against both.  This notion has been suggested numerous times in 
studies of the association between pathogens and autoimmune diseases, and is a very 
attractive mechanism.  It means that a host, by responding to a pathogen, can also be 
generating antibodies against self.  It can also help to explain why autoantibodies are not 
deleted, as they are still potentially useful against pathogens.  Potential molecular mimicry 
between autoantigens and herpesvirus antigens has been suggested for a number of 
antibodies. 
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Pp65, being the most abundant antigen in a HCMV particle, is a major target for the host 
immune system.  SLE prone NZB/W F1 mice immunised with a plasmid encoding pp65 
developed earlier onset of autoantibody production.  They developed autoantibodies against 
dsDNA and other nuclear antigens, at roughly 4 and 2 times the titres of their pre-vaccination 
levels respectively (p=0.007 and p=0.047 respectively).  Titres of anti-dsDNA did not 
correlate with the increased titres generated against pp65, indicating the increased titres found 
are not due to cross reactivity within the ELISA.  Mice vaccinated with empty plasmid did not 
produce autoantibodies at detectable levels.  Pp66 immunised mice also developed more 
severe glomerulonephritis than those vaccinated with empty plasmid (p=0.001) but did not 
show earlier mortality [98].  
Zhu et al showed that infection of keratinocytes ex vivo with HCMV induced the surface 
expression of 60kDa/Ro antigen [95].  This antigen is targeted in 30-40% of SLE patients.  
Surface expression of this normally intracellular antigen, may make it more immunogenic in 
HCMV positive individuals. 
 
 
IgM  
Patients positive for anti-HCMV IgM have worse disease activity than IgM negative patients.  
This suggests a number of possibilities.  Firstly, that HCMV reactivation is triggering flares.  
Secondly, that HCMV is reactivated during flares, or finally, that some other event is causing 
both a rise in IgM and a worsening of disease activity.   However, these findings relied 
entirely on the detection of IgM antibodies and did not detect virus.  It is therefore possible 
that non-specific antibody binding is responsible.  It is plausible that false positive anti-
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HCMV IgM is due to the presence of autoantibodies, which are found at higher levels in 
patients with worse disease activity.  In a cohort of pregnant SLE patients, those with false-
positive anti-HCMV-IgM antibodies were shown to have poorer pregnancy outcome [99].  In 
this case, false positives were defined by the apparent presence of anti-HCMV IgM when 
HCMV was undetectable in amniotic fluid or urine, and HCMV-IgG was of high avidity.  
False positive IgM antibodies may therefore be markers of more severe disease activity. 
 
Epidemiological association 
Reports on prevalence of HCMV in SLE are variable, as are reports of HCMV prevalence in 
healthy individuals.  A UK study in 1997 of 97 patients and 97 controls, found a prevalence 
of 90.87% in SLE, and a prevalence of 43.3% among the controls[100].  However, this study 
did not match controls by ethnicity. 
Experimental evidence 
UVB exposure in combination with HCMV infection causes the surface expression of 
52kDaRo antigens [101], allowing recognition of autoantigen by antibody. 
Case studies 
Along with experimental and epidemiological evidence, numerous case studies have been 
published suggesting a concurrent HCMV activation and SLE exacerbation.  HCMV has been 
associated with the onset and with exacerbation of SLE disease [96, 102-104].  There are also 
two cases of HCMV induced mortality in SLE [105], and fatal cavity lung masses in patients 
caused by HCMV [106]. 
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The relationship between HCMV infection and SLE may be caused by IFN production.  As 
Herpesvirus infection induces TLR9 stimulation and IFN production, it is possible that 
impaired control of these viruses leads to excessive IFN production, and the following 
upregulation of the IFN signature genes, resulting in increased antigen processing, increased 
T cell stimulation and ultimately increased antibody production by overstimulated or 
inappropriately stimulated B cells. 
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Associations between SLE and EBV 
 
Epstein-Barr virus has been associated with a number of autoimmune diseases, including 
SLE.  Prevalence of the virus has been shown to be higher in SLE patients than in healthy 
matched controls.  Of 196 SLE patients, only 1 lacked IgG antibodies against purified EBV 
viral capsid antigen (VCA) by ELISA.  Of the 392 controls, matched by age, sex and self-
declared ethnicity, 22 did not have antibodies against EBV-VCA (99.5% vs. 94.4%, 
P=0.014).  A subset of these patients were examined for EBV load by PCR, this also showed 
higher virus prevalence in SLE patients.  All 32 patients tested were positive by this method 
whereas only 23 of 32 controls were positive (100% vs. 72%, p<0.002).  No differences were 
seen in the prevalence of HCMV, HSV-1, HSV-2 or VZV [107].  As EBV is so common in 
the adult population, large numbers of patients and controls are needed to detect differences in 
seropositivity rates.  This issue can be avoided by using a younger cohort, in which 
seropositivity in a normal population is lower, so differences are detectable with a smaller 
cohort.  It has been shown that the presence of IgG antibodies against EBNA-1 is more 
common in paediatric SLE patients than in healthy matched controls (100% vs. 69%, 
p<0.001) [25]. 
 
EBV load is 40 fold higher in SLE than in controls, suggesting impaired control of virus 
replication [108].  This could also explain the higher virus prevalence in SLE when examined 
by PCR, as samples with lower viral loads may be below the sensitivity limit of the assay.  
Anti-viral responses by T-cells have previously been examined using HLA-tetramers and by 
ex-vivo peptide and lysate stimulation, followed by identification of any cytokines produced.  
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It has been shown that SLE patients (n=7) have a tendency towards higher proportion of cells 
responding to the HLA-A2 restricted peptide derived from BMLF-1 (p=0.07).  These authors 
also showed that among those patients with responses, fewer were capable of producing large 
amounts of IFN in response to stimulation of PBMC with the same peptide in ELISPOT 
assay [109].  It is suggested that SLE patients have increased numbers of cells, with impaired 
function, leaving the patient unable to adequately control the virus.  These findings are 
unrelated to either disease activity or treatment, however with such limited patient numbers, it 
is difficult to assess the significance of these results. 
 
It is possible that EBV presence can accelerate autoimmunity by expressing a molecule which 
results in excessive signals to autoreactive B-cells, allowing their proliferation and survival.  
LMP1 is an EBV encoded mimic of cellular CD40, this viral protein is only detectable in 
PBMCs during disease flares.  Unlike CD40, LMP1 is constitutively active and signals more 
intensely than it’s cellular counterpart.  Mice were bred to express chimeric molecules, 
comprised of the transmembrane and extracellular domains of CD40 and the intracellular 
signalling domain of LMP1.  The transmembrane and extracellular domains of CD40 were 
retained to allow the signalling to be switched on and off, as intact LMP-1 is constitutively 
active.  In these SLE-prone mice, it was shown that the excessive signalling provided by 
LMP-1, caused the mice to have enlarged lymphoid organs with more germinal centres and 
activated memory cells than their non-transgenic, SLE prone, littermates.  Furthermore, 
transgenic mice had elevated levels of autoantibodies compared to their littermates and signs 
of kidney pathology.  It is suggested that the combination of an SLE-prone background, with 
EBV induced excessive B-cell signalling accelerates autoimmune disease [110]. 
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As with HCMV antigens, EBV antigens may be triggering or exacerbating SLE by molecular 
mimicry.  BALB/c mice injected with recombinant EBNA-1 peptide developed 
autoantibodies against dsDNA.  They did not develop as fast as anti-EBNA-1 antibodies, 
leading to the suggestion that they developed as a consequence of epitope spreading, which 
resulted in antibodies being able to bind both EBNA-1 and dsDNA [111].  EBNA-1 contains 
a peptide with the sequence PPPGRRP; this sequence is very similar to a sequence found in 
the autoantibody Sm B’- PPPGMRPP.  EBNA-1 has also been shown to be a molecular 
mimic of 60 kDa Ro, animals immunised with either peptide develop antibodies against both 
antigens [112]. 
There are also numerous reports of a temporal association of EBV infection and SLE 
diagnosis [104, 113, 114].  
 
The magnitude of EBV-specific response is increased in SLE patients, compared to matched 
controls.  It has been suggested that the functional ability of these cells is impaired, 
specifically, in their ability to produce IFN[115]. 
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Research aims 
HCMV infection and carriage is asymptomatic in the context of an intact immune system. 
EBV persistence is also asymptomatic in healthy individuals.  Impairment of immune 
function by disease or chemotherapeutic agents can lead to impaired control of the viruses and 
pathogenesis. It is therefore important to consider the result these infections in Systemic 
Lupus Erythematosus:  a condition in which both disease, and its treatment modify the 
function of the immune system. 
There are a number of possible relationships between HCMV and EBV, and SLE, the aim of 
this thesis was to examine the following four hypotheses. 
  
Hypothesis 1.EBV or HCMV are necessary for development of disease.  
 If this were the case, we could expect to see 100% prevalence of the associate virus in SLE 
patients, and a significantly lower prevalence in matched healthy controls. 
 
Hypothesis 2. HCMV and/or EBV reactivate more frequently in SLE as a result of the more 
pro-inflammatory cytokine environment.   
In this case, we would expect to see elevated virus load, reflecting an accumulation of virus 
over time, and elevated T-cell and B-cell responses in order to control the viruses.   
 
Hypothesis 3.  HCMV and EBV are inadequately controlled in SLE patients, as a result of 
their impaired immune function.   
Were this hypothesis true, we could expect to see reduced frequency or magnitude of T-cell 
and B-cell responses to the virus, but higher virus loads.   
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Hypothesis 4.  HCMV or EBV are impacting on disease by causing the release of IFN, 
exacerbating disease activity or hastening the onset of disease in those infected.   
Disease activity would be more severe and disease onset would be at a younger age in those 
infected, were this hypothesis to be supported.  
 
These hypothesis are not mutually exclusive, the true nature of the relationship between 
HCMV and EBV infection with SLE is likely to be complex and multifactorial. 
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METHODS 
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Patients and Controls 
 
 Patients fulfilling 4 of 11 ACR criteria were recruited into the study at the Wellcome 
Trust Clinical Research Facility.  All patients and controls gave informed written consent.  
SLE patients donated blood samples on recruitment; further samples were taken at subsequent 
clinic visits, with a minimum interval of three months.  86 SLE patients were recruited, giving 
253 samples. Healthy controls (n=48) were selected based on their lack of family history of 
autoimmune disorder; they donated blood samples on one occasion only.  Healthy controls 
and SLE patients were matched for age (43.23±1.858 vs. 40.73±1.272, mean ± SEM, 
p=0.4132) sex (9.3% male vs. 9.2% male).  Patients and controls were identified as HCMV+ 
if the first sample tested positive by in-house developed ELISA for anti-HCMV IgG.  
Clinically, the presence of anti-CMV IgG is considered definitive of previous HCMV 
infection[99].  Patients and controls were considered EBV positive if any two of the 4 
methods used (EBV IgG ELISA, EBV VCA, EBV load, anti-EBV IFN response) returned a 
positive result, in the first sample given.  This was necessary as not all samples were tested by 
all available methods, and correlation between methods was unreliable.  Samples with 
inconclusive viral positivity were not included in comparisons between virus positive and 
virus negative populations, but were included in comparisons between controls and SLE 
patients.  This study has been approved by the Birmingham, East, North and Solihull 
Research Ethics Committee. 
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Sample preparation 
Blood samples of 20ml were taken by venepuncture into heparinised tubes from patients and 
controls.  Samples were mixed 1:1 with RPMI (Sigma-Aldrich) and layered onto 15ml Ficol.  
Samples were spun at 1800rpm for 30 minutes and the resulting PBMC layers and 
plasma/RPMI mixture collected.  PBMC were then washed in RPMI, and either used fresh for 
intracellular staining or frozen for DNA extraction and tetramer staining.  PBMCs were stored 
at <10 x 10
6
/ml in FCS +10% DMSO at -80c in liquid nitrogen.  Two aliquots of 
plasma/RPMI mix were retained per sample and frozen at -80c for serological analysis.   
 
HCMV IgG 
 
Maxisorb plates (NUNC ebioscience) were coated overnight at 4
c with 50μl of lysed 
uninfected fibroblasts or HCMV infected lysed fibroblasts at 5ng/l.  Plates were then washed 
three times with PBS (0.05% Tween20).  Plasma/RPMI was diluted to 1/450 and incubated 
on the plate for 30 minutes at room temperature.  After washing three times with PBS (0.05% 
tween 20), anti-human IgG monoclonal antibody conjugated to HRP was added (eBioscience) 
for another 30 minutes at room temperature.  Plates were washed another three times then 
antibody substrate added for 10 minutes.  The reaction was stopped using 100µl 1M HCl and 
optical density (OD) read at 450nm.  The OD of binding to uninfected fibroblast lysate was 
subtracted from the OD binding to infected lysate to give a measure of binding to HCMV 
specific proteins.  Arbitrary units of antibody binding were assigned to samples by 
comparison to a standard, using a sigmoid dose response curve fit, with a maximum of 1000 
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units.  A cut off of 10 units was assigned, having two points of the standard curve below it, 
and 4 points above, and being at the bottom of the linear section of the sigmoid curve. 
HCMV IgM 
Plasma anti-HCMV IgM was measured by ELISA, using a kit from IBL international 
designed to detect the presence of IgM antibodies against HCMV antigens.  Samples were 
diluted 1/50 in the provided diluent, to account for the previous ½ dilution in RPMI.  Tests 
were then run according to manufacturer’s instructions.  Results were calculated as a 
proportion of the provided reference control, and are therefore only semi-quantitative.  Both 
equivocal and clear positive samples were considered positive, samples giving an OD reading 
of >90% of cut off control were considered positive.  As samples are diluted 1:1 in RPMI, 
guidelines for seropositivity cannot be considered completely accurate. 
EBV IgG ELISA 
Samples were tested using ELISA kits supplied by IBL international, designed to test for the 
presence of IgG antibodies against EBNA-1 antigen.  Samples were diluted to half the 
recommended dilution to account for the previous 1:1 dilution in RPMI, the according to the 
manufacturers instructions.  Both clear positive and equivocal samples were considered 
positive, therefore samples were considered positive at >12U/ml. Again, as samples are 
diluted 1:1 in RPMI, supplied guidelines for seropositivity can not be considered completely 
accurate. 
EBV IgM ELISA 
Relative anti-EBV EBNA-1 IgM titres were determined using ELISA assays form IBL 
international designed to test for the presence of IgM antibodies against EBNA-1.  Samples 
were run according to manufacturers instruction with the exception of the dilution factor, 
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being half that prescribed.  Samples were also pre-incubated with anti-rheumatoid factor 
serum to remove confounding antibodies, which could lead to false positive results. Both 
clear positive and equivocal samples were considered positive, samples were considered 
positive at >8U/ml.  As samples are diluted 1:1 in RPMI, guidelines for seropositivity cannot 
be considered completely accurate. 
 
EBV IgG Immunofluorescence 
IgG antibodies specific for viral capsid antigen (VCA) were detected by immunofluorescence.  
EBV positive (P3HR1) and EBV negative (BJab) cells were applied to glass microscope 
slides at 10 x 10
5
 per 20µl well and air-dried at 37
o
c for up to 14 hours.  Cells were then fixed 
in ice-cold acetone for 10 minutes, and stored at -20 until needed.  Plasma/RPMI was diluted 
1/10 in PBS supplemented with 10% heat inactivated goat serum (HINGS).  20l was applied 
to cells and incubated for 1hr at 37c.  Slides were washed for 10 minutes in PBS and stained 
with anti-human IgG  chain specific FITC conjugated antibody for 30 minutes at 37c 
(Sigma).  Slides were then washed and mounted using 0.05% DABCO glycerol mounting 
media and examined at 400x magnification.  Positive samples were identified as those causing 
homogenous staining of around 1/10 B-cells at a dilution of 1/10.  Samples showing strong 
autoantibody binding were diluted to 1/40, 1/80 and 1/160.  Those in which autoantibody 
staining remained at the lowest dilution, were excluded from this set of results as 
autoantibody staining interfered with identification of anti-VCA staining. 
Tetanus 
Anti-tetanus toxoid IgG was measured in the first supplied sample using an ELISA kit 
supplied by Demeditec. The assay was sensitive to 0.004IU/ml (WHO 76/589). Assays were 
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performed according to manufacturers instructions, with the exception of the sample dilution 
factor.  Samples were diluted by half the factor suggested.  
IFN ELISA 
Plasma IFN concentrations were measured using kits supplied by R and D Systems, using 
the sandwich principle to quantify IFN in media.  Plasma/RPMI mix was applied neat to the 
wells.  Plasma IFN levels were calculated based on this 1:1 dilution. 
T-cell assays 
HCMV lysate production 
Human foetal foreskin fibroblasts were cultured in DMEM supplemented with 10% FCS, 
2mM L-glutamine and 1% penicillin/streptomycin.  Fibroblasts were grown to 70% 
confluence then infected with AD169 at 4:1 MOI.  Supernatant was collected every 8 days, 
pooled, and ultra-centrifuged at 12000 rpm for two hours.  Fibroblasts were harvested after 
they had detached themselves from the flask.  Supernatant pellet and harvested fibroblasts 
were added together and exposed to multiple rounds of freezing in liquid nitrogen, and 
thawing at room temperature.   The mixture was then sonicated to break up large particles, 
and irradiated to destroy any remaining live virus. 
Intracellular staining 
Freshly isolated PBMC were stimulated with 10µl HCMV lysate, HCMV peptide mixes, and 
EBV peptide mixes (see tables 2 and 3) for 18 hours, the last 17 being in the presence of 
BFA, in 500µl RPMI supplemented with 10% FCS and 1% penicillin/streptomycin.  
Staphylococcus enterotoxin B (SEB) was used as a positive control.  Cells were then washed 
in MACS buffer and stained for surface markers for 30 minutes at 4
o
c in 100µl MACS buffer 
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(see table 1).  See appendix 2. for gating strategy.  Following another wash, cells were fixed 
using 100µl 0.4 % PFA.  Cells were then washed and permeablised using 100µl 0.5% saponin 
and intracellularly stained for IFN.  Excess antibody was removed by washing with MACS 
buffer and cells were analysed within 2 hours by flow cytometry using LSRII (BD 
Bioscience). 
 
Cells were gated using forward scatter height and area to identify single cells, single PBMC 
were identified by their forward and side scatter properties.  Single PBMCs were gated based 
on the presence of CD3 to identify T-cells, then on the presence of CD4 or CD8.  Cells 
bearing both CD4 and CD8, and those bearing neither, were excluded.  CD4+ and CD8+ were 
then categorised by the presence or absence of CD28, CD27 and CD57. 
 
 
Specificity Colour Supplier 
CD8 AmCy BD 
CD4 PeCy7 e-biosciences 
CD57 PE  biolegend 
CD28 PerCPCy5.5 e-biosciences 
CD27 APC-Cy7 e-biosciences 
CD3 APC  invitrogen 
IFNg FITC BD 
 
Table 1: Antibody staining panel for intracellular staining 
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  EBV lytic EBV Latent 
HLA Code Peptide Code Peptide 
A2    FLY LMP-2 
A2.01 GLC BMLF-1   
A2.01 YVL BRLF-1   
A2.01   CLG LMP-1 
A24 DYC BRLF-1   
A24   TYG LMP-2 
B27 ARY    
B27.02/.04/.05   RRI EBNA-3C 
B27.05   HRC EBNA-3B 
B35.01 EPL BZLF-1   
B35.01   HPV EBNA-1 
B35.01   YPL EBNA-3A 
B38   YHL EBNA-2 
B44.03   EGG EBNA-3C 
B45 AEN    
B7   RPP EBNA-3A 
B8 RAK BMLF-1   
B8   FLR EBNA-3A 
B8     QAK EBNA-3A  
 
Table 2: EBV lytic and latency peptide panels, used for stimulation of CD8+ T-cells. 
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IE-1 peptide mix     
HLA restriction CD4/CD8 Peptide sequence 
A68 CD8 ATTFLQTMLRK 
B40 CD8 KEVNSQLSL 
B8 CD8 QIKVRVDMV 
B44 CD8 DELRRKMMY 
B8 CD8 ELRRKMMYM 
B8 CD8 ELKRKMIYM 
B27 CD8 KRKMMYMCY 
B55 CD8 FPKTTNGCSQA 
A1/B18 CD8 CVETMCNEY 
B7 CD8 CRVLCCYVL 
A2  CD8 YVLEETSVML 
B27 CD8 RRIEEICMK 
B44 CD8 EEAIVAYTL 
A2 CD8 VLEETSVML 
   
pp65 peptide mix     
HLA restriction  CD4/CD8 Peptide sequence 
A68 CD8 DTPVLPHETR 
B35 CD8 QPSLILVSQY 
A68 CD8 YTPDSTPCHR 
B35 CD8 CPSQEPMSIY 
A24 CD8 VYALPLKML 
B35 CD8 IPSINVHHY 
A68 CD8 FVFPTKDVALR 
B35 CD8 FPTKDVAL 
A24 CD8 QYVKVYLESF 
B7 CD8 RPHERNGFTVL 
B35 CD8 QAIRETVELR 
A24 CD8 QYDPVAALF 
A1  CD8 YSEHPTFTSQY(HPTFTSQY) 
B7 CD8 TPRVTGGGAM 
A2 CD8 NLVPMVATV 
A2 CD8 RIFAELEGV 
DR7 CD4 PDVYYTSAFVFP 
DR4 CD4 IIKPGKISHIMLDVA 
DR11 CD4 PQYSEHPTFTSQYRI 
DR11 CD4 FTSQYRIQGKLEYRHT 
DR ? CD4 AGILARNLVPMVATV 
DR52 CD4 KYQEFFWDANDIYRI 
   
pp50/gB/gH peptide mix     
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HLA restriction (and protein) CD4/CD8 Sequence 
A1 (pp50) CD8 VTEHDTLLY  
DR7 (gB) CD4 DYSNTHSTRYV 
DR7 (gB) CD4 VFETSGGLVVFWQGI 
DR4 (gB) CD4 CMLTITTARSKYPYH 
DR11 (gH) CD4 HELLVLVKKAQL 
   
Table 3: HCMV peptide mixes used to stimulated CD4+ and CD8+ T-cells.  
Tetramer staining 
PBMC were defrosted in PBS and vital dye was added to identify dead cells for exclusion.  
Cells were washed and transferred to MACS buffer.  Tetramers were added, based on the 
patient or control’s HLA type for 15 minutes at 37c.  Cells were washed again in MACS 
buffer and antibodies added against surface phenotypic molecules for 30 minutes at 4

c.  Cells 
were washed once more and examined using flow cytometry via LSR II (Beckman coulter).  
Cells were gated using the same method as that employed for intracellular staining, however a 
vital dye stain was added so dead cells could be excluded. 
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 HCMV EBV 
HLA type code protein code protein 
A1 VTE pp50 - - 
A1 YSE pp65 - -- 
A2 NLV pp65 GLC BMLF-1 (lytic) 
A2 VLE IE-1 CLG LMP-1 (latent) 
B7 RPH pp65 RPP 
EBNA-3A 
(latent) 
B7 TPR pp65   
B8 ELR IE-1 RAK BMLF-1 (lytic) 
B8 ELK IE-1 FLR 
EBNA-3A 
(latent) 
B8 QIK IE-1   
 
Table 4: HLA tetramer specificities. 
 
DNA extraction 
DNA extraction was performed using QIAamp DNA mini kits from QUIAGEN, according to 
manufacturers instructions.  DNA was extracted from 1 x 10
6 
PBMC pellets, which had been 
stored at -80
o
c since collection.  DNA was stored in 50µl water at -80 until needed. 
 
HLA typing  
Patient and control DNA samples were used to identify those expressing HLA A1, A2, B7 
and B8, so that only the relevant tetramers were applied to samples.  A method developed by 
Bunce et al was adapted for this purpose [116].  PCR products were examined by gel 
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electrophoresis on Tris-Borate-EDTA gel.  Lanes showing bands at the correct molecular 
weight for the specific primers were considered positive. 
 
 
EBV load PCR 
The number of copies of EBV genome per million PBMCs was measured using EBV BALF5, 
a gene encoding EBV polymerase.  Three master mixes were made for each sample, 
containing 2µM forward and reverse POL primers, 5µM POL probe, 3µM β2m forward 
primer, 4µM β2m reverse primer and 5µM β2m probe, to give a total volume of 7.5µl.  To 
this mix was added 12.5µl Taqman Universal 2x primer mix and 5µl DNA sample.  Samples 
were run in 96 well plates, using an ABI7500 (Applied Biosystems). Primers are shown in 
table 5 
 
 
 
    
BALF5   
Forward primer CTT TGG CGC GGA TCC TC 
Reverse primer AGT CCT TCT TGG CTA GTC TGT TGA C 
Probe (FAM) CAT CAA GAA GCT GCT GGC GGC C (TAMARA) 
β2m   
Forward primer GGA ATT GAT TTG GGA GAG CAT C 
Reverse primer CAG GTC CTG GCT CTA CAA TTT ACT AA 
Probe (VIC) AGT GTG ACT GGG CAG ATC ATC CAC CTT C (BHQ) 
  
Table 5: Primers and probes for quantification of EBV. 
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Ethical considerations 
All laboratory data and clinical data were compiled and organised using Microsoft Excel.  
Patients were identifiable in this study only by an anonymous reference number.  Date of birth 
was used for confirmation of identity.  Controls were identified only by the use of an 
anonymous reference number.  Controls were given the opportunity to provide their age, sex 
and self-declared ethnicity.  Control recruitment was from amongst staff at Queen Elizabeth 
Hospital Birmingham UK and City hospital Birmingham UK.  Controls were also recruited 
using the University of Birmingham’s Health research bus, a mobile research facility, for this 
study located in Birmingham city centre.  
Clinical information 
Clinical information and patient information were collected using Patients Informatics 
Consult Service (PICS) software, using the patient’s anonymous reference number, and date 
of birth.  Disease activity, damage index, CRP, C3, C4, dsDNA, medication and lymphocyte 
count were collected for the day of blood donation.  Total disease activity was calculated by 
assigning any A values a score of 12, any B values a score of 5, and any C values a score of 1.  
The total disease activity score is the sum of all systems. Any missing data values were 
entered as the mean of previous and subsequent clinic visit, as missing data were not available 
at submission.  See appendix 1. for full disease activity and treatment details. 
Statistics 
Data were analysed and presented using Graphpad Prism.  Correlations were all assessed 
using Spearman’s rank.  Other data were all compared using the Mann-Whitney test when 
data was not normally distributed (as assessed using D’Agostino and Pearson omnibus 
normality test), of T-test when data was normally distributed.  χ2 analysis was used to 
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compare differences between populations.  Kruskal-Wallis in combination with Dunns test 
was used for comparisons of more than two groups.  All tests were two tailed.
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Results 1: Serology 
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Introduction 
When considering the association between HCMV and EBV and SLE, it is important to 
consider how common the virus is within the disease population, compared to a matched non-
disease control population.  If the virus is more prevalent in the disease population it is 
possible that the virus is contributing to aetiology, or the disease population is more 
susceptible to virus infection.  If the virus is found in 100% of the disease population it is 
possible that the virus is necessary for disease, and if the virus is less common in disease, it is 
unlikely to be a major contributing factor, or may be less readily acquired by those with 
disease.   
It is also important to consider the magnitude of anti viral responses, as differences may 
reflect alterations in ability to control virus reactivation.  SLE patients are immuno-
suppressed, due to disease and treatment, it is therefore important to assess whether viral 
control is adequate. 
HCMV prevalence is higher in older populations, the sero-conversion rate has been estimated 
to be 0.55% per year, and can occur at any age [70].  As infection is generally asymptomatic 
it is difficult to determine when an individual has become infected.  Incidence in younger 
people compared to older members of the same population can give clues regarding age of 
seroconversion in different groups.  This is not an ideal method but is used here as a surrogate 
in place of a longitudinal study.  If incidence is more common in younger members of one 
population, than younger members of a different population, it suggests that the first 
population has a tendency to acquire the virus at a younger age. 
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If differences in prevalence or anti-viral response do occur between populations, it is 
necessary to know whether the difference is specific for the type of virus being studied, and 
its pattern of persistent infection over the lifetime of the host.  For this purpose, the immune 
responses to tetanus toxoid, a temporary immune challenging antigen, have been used.  
Tetanus vaccine responses are almost ubiquitous, and tetanus vaccination is not contra-
indicated in SLE. 
Both HCMV and EBV are only clinically relevant in pregnancy and immunocompromised 
hosts.  In these situations, HCMV antigen and DNA are detectable.  As it is difficult to detect 
antigen or DNA in healthy controls, for the purpose of this study, the determination of virus 
carriage is made using the detection of antibodies.  HCMV seropositivity is determined by the 
presence if anti-HCMV IgG.  Anti-CMV IgM antibodies are made early in infection but 
persist in some individuals.  IgG avidity is used in pregnant women to determine whether the 
presence of anti-HCMV IgM represents a primary infection or a virus reactivation [117].  
Low avidity IgG antibodies are found early in infection, so the presence of these combined 
with the presence of IgM antibodies, represents a recent infection.  IgG avidity increases over 
time, so the presence of high avidity antibodies indicates a less recent infection.  EBV IgG 
and IgM serological responses are also considered in this chapter.  EBV DNA is detectable in 
healthy controls, and will be examined in chapter three. 
 
This chapter also examines IFN concentrations in plasma, and how this relates to viral 
infection.  SLE patients have up-regulated expression of IFN inducible genes, and higher 
IFN concentrations are associated with the worst disease activity.  HCMV and EBV 
infection of plasmacytoid dendritic cells causes the release of IFN [118].  Although it has 
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been shown that CMV seropositivity does not affect concentration of IFN in plasma in 
healthy individuals[119] it is possible that HCMV infection is associated with IFN in SLE.   
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Results 
EBV seropositivity has, for the purpose of this study, been defined as the identification of IgG 
antibodies against VCA, or the presence on IgG antibodies against EBNA-1.  HCMV 
seropositivity has been defined as the presence of IgG antibodies against HCMV infected, 
lysed fibroblasts. 
  
                 
 Control  SLE   
  n % Negative % Positive   n % Negative % Positive P value 
CMV IgG ELISA 48 39.58 60.42  72 51.39 48.61 0.2041 
CMV IgM ELISA 23 91.30 8.70  52 61.54 38.46 0.009 
EBV IgG ELISA 35 11.43 88.57  61 18.03 81.97 0.391 
EBV IgM ELISA 35 65.71 34.29  60 78.33 21.67 0.1779 
EBV IgG VCA 25 4.00 96.00   27 3.70 96.30 0.9557 
         
 
Table 6: Percentages of controls and SLE patients HCMV and EBV positive by each 
method used, at the first sample donation. Borderline and clear positive samples have been 
included as positive in commercially available assays.  Samples showing fluorescence at 
1/10 have been considered positive. 
 
 
 
 
There is no significant difference in the prevalence of EBV infection as measured by the 
presence of anti-EBV IgG, between SLE patients and healthy controls, using either method 
employed (Table 6).  Anti EBV IgG was measured by ELISA, measuring titre of anti-EBNA-
1 IgG, and by immunofluorescence, identifying the presence of IgG antibodies against VCA.  
IgG antibody responses to EBV by ELISA and IFA are not of similar frequency. In SLE 
patients and controls there was not an exact correlation between the presence of anti VCA 
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antibodies and anti EBNA-1 antibodies.  22% of SLE patients tested by both methods carried 
anti-VCA-IgG, but no anti-EBNA-1 IgG.  13% of controls shared this response.  No members 
of either population had anti-EBNA-1 responses without anti-VCA responses (p=0.5098 by 
χ2).  Detection of anti VCA antibodies by IFA is more sensitive that detection of anti-EBNA-1 
antibodies by ELISA.  Five patients' samples contained too high a concentration of 
autoantibodies to allow detection of the presence or absence of anti-VCA antibodies.  
Autoantibody binding to all B-cells made the identification of binding to VCA antigens on 
around 1/10 EBV infected B-cells difficult.  Alternative samples, from later donations, were 
available which allowed detection of anti-VCA antibodies in all but two patients.  These two 
were excluded from analysis for this method.   
There was no significant difference in the frequency of detection of anti EBNA-1 IgM 
antibodies in SLE patients and controls.  The frequency of anti EBNA-1 IgM antibodies in 
SLE patients was not significantly different from expected data supplied by manufacturer 
(84.1% negative of 88 samples, vs 78.33% negative SLE patients p=0.3732 χ2).   Control 
samples did show significantly higher seropositivity than the data supplied by the 
manufacturer (p=0.0243). 
   
There was no difference in the frequency of detection of anti-HCMV IgG antibodies between 
SLE patients and controls.  The prevalence of HCMV was similar to that previously reported 
[120].  It was not possible with this size of population to identify any differences in 
seroprevalence between males and females.  The percentage of SLE patients testing positive 
for anti HCMV IgM antibodies is significantly higher that that found in controls.   
As HCMV prevalence is thought to increase with age, patients and controls were split into 
two populations, based on being older or younger then the median age of 43.  Younger SLE 
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patients had similar seropositivity rates to younger healthy controls (47% vs. 37.5% 
respectively, p=0.5052), whereas older SLE patients were less likely to be HCMV 
seropositive (50% vs. 89% respectively, p=0.0043).  Healthy controls have higher 
seropositivity rates in the older group than the younger group (89% vs. 37.5% respectively, 
p<0.0001), whereas SLE patients have similar prevalence in young and older groups (47% vs. 
50% respectively, p=0.826).   EBV seropositivity by either method does not show any 
association with age in either population. 
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Figure 1: IgG and IgM titre in response to HCMV, EBV and Tetanus ELISAs. Only IgG 
seropositive individuals have been included for HCMV and EBV.  Tetanus data is 
representative of the whole cohort.  IgG antibody titres are shown as arbitrary units from a 
quantitative scale. IgM antibody titres are shown as arbitrary units from a semi-
quantitative scale.  Bars represent mean values ± SEM. 
  65 
 
Anti-HCMV IgG titres are elevated in SLE compared to healthy controls (Figure 1 p=0.0436).  
IgG binding to autoantigens has been excluded by the use of an uninfected control.  IgG 
binding to unifected fibroblasts is elevated in SLE patients (Data not shown p=0.0009), but 
has been accounted for in the results.  Anti-HCMV IgM titres are also elevated in SLE 
patients.  The anti-HCMV IgM assay does not account for the presence of autoantibodies, but 
anti-HCMV IgM binding to unifected fibroblasts is not elevated (data not shown p=0.26).   
Anti-EBV IgG titres are elevated compared to controls.  Anti-EBV IgM titres are similar in 
SLE patients and healthy controls.  The assay used to determine EBV titres, uses EBNA-1 
peptide as antigen, therefore risk of non-specific autoantibody binding is minimal.  The 
magnitude of IgG response to tetanus toxoid is similar in SLE patients and healthy controls.   
77% of SLE patients had protective antibody titres against tetanus as defined by the presence 
of >0.1IU/ml (WHO 76/589).  85% of controls had protective antibody titres by the same 
criteria (p=ns). 
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Figure 2: Association of IgG titre with age.  Each point represents an idividual's age and 
IgG titre at the first sample donation.  IgG titres are arbitrary units from a quantitative 
scale. Only positive individuals have been included for HCMV and EBV. 
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As seroprevalence increases with age in conrols but not SLE patients, we wished to further 
investigate the relationship between age and antiviral responses.  In controls, anti-HCMV titre 
correlates with age (Figure 2, p=0.0165).  This is not the case in SLE patients.  IgG titres are 
increased in older controls (>43), compared to younger controls (p=0.0272 t-test), but there is 
no difference in titre in SLE between older and younger patients.  Anti-HCMV IgM titre is 
not correlated with age in controls or SLE patients (data not shown).  Anti-EBV IgG titres are 
not correlated with age in SLE patients or controls.  Anti-EBV IgM titre is not correlated with 
age in controls, but is negatively correlated with age in SLE patients (data not shown 
p=0.0246).  There is no correaltion between anti-CMV IgG titres and anti-EBV IgG titre in 
controls or SLE patients (data not shown p=0.8933 and p=0.6680 respectively). 
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Figure 3: IFN concentrations in plasma.  (A) Plasma IFN in controls and SLE patients.  
Bar represents mean value. (B) Control and SLE plasma IFN concentration in HCMV 
negative and HCMV positive individuals.  Bars represent mean ± SEM.  IFN 
concentration is shown in pg/ml. 
 
There is, as shown previously, no difference in IFN concentration in SLE and control 
plasma (Figure 3).  Among SLE patients, HCMV positivity is associated with reduced plasma 
concentrations of IFN (p=0.029).  HCMV seropositivity does not affect plasma IFN levels 
in healthy controls (p=0.4124).  There was no association between EBV posivitity by any 
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method and plasma IFN concentrations (data not shown).  There was also no relationship 
between the magnitude of anti-HCMV or anti-EBV response and IFN concentration.  IFN 
levels are not associated with the age of SLE patient or healthy controls, nor with age of 
diagnosis or time since diagnosis. 56% of SLE patients have detectable levels of IFN 
(>0pg/ml).  41% of controls had detectable levels of IFN using the same criteria (p=ns).   
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Discussion 
SLE patients have previously been reported to have increased EBV seroprevalence relative to 
controls, in both paediatric and adult populations [25, 108].  This is not the case in this study, 
by both ELISA and IFA, SLE patients showed similar prevalence to controls.  However, the 
presence of anti-EBNA-1 antibodies as detected by ELISA, does not always correspond with 
the presence of anti-VCA antibodies by IFA.  Anti-VCA-antibodies have been detected, in the 
absence of anti-EBNA-1 antibodies.  This serological pattern was also identified in 11.8% of 
samples in a study in 2009 [86].  Anti-VCA antibodies normally develop before anti-EBNA-1 
antibodies, and maintain a higher titre [121].  Therefore, those that are positive only by VCA 
may have been recently infected, or they may have not yet developed a high enough anti 
EBNA-1 titre to be detected.   
While HCMV seroprevalence is similar between SLE patents and controls when entire 
populations are considered, there are significant differences in prevalence in the older half of 
the population.  Controls' seroprevalence increases with age, as does anti-HCMV IgG titre.  
The increase in seroprevalence in older people has been reported previously [120].  This is not 
the case in SLE, both seroprevalence and titres are similar in the older and younger patients.  
This indicates that SLE patients are not acquiring the virus at a similar rate to controls, 
possibly because they acquired it at a younger age.  However, in this study younger patients 
(<43) had similar seroprevalence to younger control.  The only difference exists in those older 
patients.  It is possible that SLE patients do not acquire the virus as efficiently as healthy 
controls.  This may be due to social factors, disease activity or disease treatment.  It has been 
impossible in this study to control for social factors, and no differences were discovered 
between those who acquired the virus and those who didn't in terms of disease activity or 
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treatment.  It may be that the immune environment in SLE patients is not conducive to 
infection, either because of disease characteristics or because of treatment (to be discussed in 
more detail later). 
It has not been possible to identify any association with age and EBV seroprevalence, likely 
due to the very low frequency of EBV negative individuals.  A larger cohort would be 
necessary to test any association. 
The only antibody specificity to show a difference in prevalence between SLE and controls is 
anti-HCMV IgM.  Increased positive IgM antibodies may be representative of increased 
CMV reactivation in SLE patients compared to healthy controls.  The presence of anti-HCMV 
IgM antibodies in SLE patients has been associated with worse disease activity, and it has 
been suggested that virus reactivation exacerbates disease [122].  However, SLE patients have 
an increased rate of false IgM positivity, defined by the lack of anti-HCMV IgG, and the 
presence of anti-HCMV IgM antibodies.  Of 21 SLE patients negative by IgG, six had 
apparent IgM antibodies.  No IgG negative controls had IgM antibodies. Patients with 
autoimmune diseases do have increased rates of false positive IgM antibodies.  The presence 
of false positive IgM in pregnancy, among patients with autoimmune diseases, was associated 
with worse outcome, including earlier delivery and lower birth weight [99].  It is possible that 
the elevated level of IgM binding to HCMV assays in SLE patients is the result of 
autoantibody binding, levels of which are elevated in patients with worse disease activity.  
The alternative explanation for the presence of IgM antibodies without IgG antibodies is that 
they are experiencing a primary infection, or have delayed class switching.  A small study in 
1996 of immunocompromised patients found that those undergoing a primary infection had 
significantly delayed maturation of the IgG response and maintained IgG response longer than 
immunocompetent individuals [123].  Determination of IgG avidity would have been useful 
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in clarifying this situation.  However, given the available data, it seems unlikely that 28.6% of 
patients are experiencing a primary infection.  It is more plausible that the elevated IgM 
seropositivity in SLE is a result of false positives, possibly due to autoantibody binding to the 
plate.  Indeed, when only anti-HCMV IgG positive individuals are included, there is no 
difference in the prevalence of anti-HCMV IgM between SLE patients and controls 
(p=0.1804 χ2).  False positives are more common in SLE patients, for diseases such as HIV 
[124] syphilis, and SARS [125], due to cross-reaction of autoantibodies in laboratory assays. 
There was no difference in anti-EBV IgM seropositivity between SLE patients and controls, 
suggesting there are no differences in the frequency of EBV reactivation in these populations.  
Controls showed higher seropositivity than predicted by the kit manufacturer, probably due to 
differences in the population being studied.  EBV seropositivity is less common in those with 
higher socioeconomic status, infection is associate with lower paternal education, smoking 
and in females [93].  Using different groups of healthy people can therefore give very 
different results.  It is also possible that by diluting plasma in RPMI 1:1 then using half the 
dilution factor suggested by the manufacturer, that interfering factors were introduced to the 
assays causing elevated antibody binding. 
 
Anti-HCMV IgG titre is elevated in SLE patients compared to controls, this may be indicative 
of elevated HCMV load, requiring additional humoral control.  Anti HCMV IgG responses 
may be elevated due to antibody binding to self-peptides expressed as a result of HCMV 
infection.  HCMV infection causes a number of changes to occur within the cell and the 
expression of a number of antigens.  Antibodies may be binding antigens expressed as a result 
of the intracellular changes that occur on infection.  Infection of fibroblasts with HCMV 
causes the expression of 60kDa Ro/SSa antigens, although these are not expressed on the cell 
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surface, lysing of infected cells would cause these antigens to be available for binding in 
ELISA [101].  35% of SLE patients have antibodies against this antigen [126].  
Anti-EBV EBNA-1 IgG titre is also elevated in SLE patients compared to controls, indicating 
elevated requirement for virus control, possibly due to increased EBV load or impaired 
cellular control.  These aspects will be discussed in chapters 3 and 2 respectively.  The EBV 
assay measures binding to peptides, minimising the potential for false positives, although, the 
peptide used, EBNA-1, has been shown to be a molecular mimic of the autoantigen Sm.  Sm 
autoantibodies present in SLE patients, these may be responsible for the elevated binding. 
Anti-EBV IgG antibodies were also found among patients with rheumatoid arthritis, 
population with similar treatment regimen to SLE patients [127]. 
Anti-tetanus IgG responses are not elevated in SLE patients; increased HCMV and EBV 
responses are therefore not the result of hypergammaglobulinemia. 
Increasing anti-HCMV IgG titres with age in controls may reflect increasing virus loads, 
requiring increased immune control.  It is also possible that this increase in titre is the result of 
an accumulation of  herpes specific responses, either due to constant immune stimulation or 
as a result of a small acumulation with every period of virus reactivation.  Anti-HCMV IgG 
titre may therefore refect the time since infection, but as we are unable to determine date of 
primary infection, it is not possible to confirm this hypothesis. 
EBV responses do not increase with age in this population. There was also no association 
found between anti-EBV response and sex, although with only 1/10 SLE patients being male, 
the difference would have to be massive to be detected.  A study in Texas showed that anti-
EBV IgG responses are higher in older people, and in females, however this study involved 
2706 people, giving it considerably more power [128].   
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As the anti-VCA-IgG antibody assay was not quantitative, it was not possible to examine an 
association between anti-VCA titre and anti EBNA-1 titre.  Anti-tetanus IgG titre does not 
increase with age in controls or SLE patients.  Tetanus infection, unlike HCMV infection, is 
not a lifelong challenge to the host, and it is possible therefore, that it does not require an 
increase in humoral control.  EBV however, is a persistant virus, requiring consistant control, 
but unlike HCMV anti-EBV IgG titre does not increase suggesting the increase is HCMV 
peculiar to HCMV. 
 
Increased anti-HCMV IgM titres in SLE patients may be explained by the presence of 
autoantibodies.  These would bind to non-HCMV peptides on the ELISA plate, giving a 
falsely elevated result.  The other antibody assays used are not susceptible to this interference, 
as they are either coated with peptide alone, or autoantibody binding is accounted for by use 
of an uninfected control.  
The decrease in anti-EBV IgM response in older people may reflect reduced frequency of 
reactivation in older patients.  However, since a number of SLE patients are likely to have 
false positive IgM results, it may be that the frequency of false positivity reduces with age.  
This may reflect changes in the pattern of disease activity, as patients get older.   
 
Plasma IFN concentration is not elevated in SLE patients relative to healthy controls as 
shown previously.  SLE patients have lower serum IFN levels if HCMV seropositive, 
compared to seronegative.  This data does not obviously fit with the fact that HCMV infection 
of pDCs causes the release of IFN [129].  However, it is well know that HCMV makes use 
of multiple immunomodulatory mechanisms, the ability to impair production of an 
inflammatory cytokine would be of benefit to HCMV.  IFN causes the up-regulation of anti-
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viral function in a number of immune cell types.  It causes the upregulation of MHC I 
molecules, increasing T-cell recogmition of infected cells, enhances NK killing, and supports 
the differentiation of monocytes into antigen presenting DCs [129].  It has also been 
suggested that IFN causes the differentiation of naïve CD4+ T-cells into IGN producing T-
cells [130].  There is no evidence that HCMV downregulates IFN expression, but given the 
viruses other immunomodulatory abilities, it is not inplausile.  
Alternatively, HCMV infection may be overstimulating pDCs causing them to become 
annergic and unable to produce more IFN. Repeated stimulation of pDCs via toll-like 
receptor ligation resulted in reduction of IFN production capacity.  However, the ability to 
produce IFN was regained after 24 hours without stimulation. 
Conversely, SLE patients with the highest IFN concentrations may be protected from 
HCMV infection. 
 
Serological responses in SLE patients are similar to, or exceed those found among controls, it 
is therefore likely that these responses are adequate to control virus. This indicates that neither 
disease itself nor its treatment has a detrimental effect on the humoral immune response to 
HCMV or EBV. 
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Results 2: Cellular responses 
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Introduction 
T-cell responses are fundamental in the control of herpes viruses, inadequate responses, such 
as those found post allogeneic stem cell transplant and in HIV patients, lead to virus 
reactivation and pathogenesis.  Post transplant, HCMV specific cell counts of 10
6
 to 20 x 10
6
 
cells/L are protective against HCMV disease [131].  Adoptive transfer of HCMV specific 
lymphocytes, generated from the stem cell donor, is used post transplant to prevent and treat 
viral reactivation [129].  In HIV patients, frequency of HCMV specific cytotoxic CD8 T-cells 
correlates with protection form HCMV disease [129]. 
 
Expansions of HCMV specific CD8+ T-cells are found in older people, as determined by both 
tetramer staining and IFN production [129].  These cells remain functional, suggesting the 
increase in frequency is not driven by an accumulation of anergic cells [132].  HCMV specific 
CD4+ T-cells account for around 1-2% of peripheral CD4+ T-cells in seropositive people, 
although some individuals have much higher frequencies.  HCMV specific T-cells frequently 
target pp65, and are either CD45RA+ CD45RO+, or an effector memory phenotype.  HCMV 
specific CD4-T-cells are capable of producing IFN and TNF, identifying them as part of 
the Th1 subset [133].  A small study by Bitmansour et al showed that healthy carriers 
generally have 1-3 dominant clonotypes of CD4+ HCMV specific T-cells, as defined by TCR 
V usage.  This population accounted for up to 50% of the total HCMV response, and up to 
4% of peripheral blood CD4+ T-cells [129].  A decline in CMV specific cell frequency post-
renal transplant is predictive of HCMV disease [134], indicating the necessity of adequate 
CD4+ T-cell responses. 
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T-cells are also crucial for the control of replication of EBV after primary infection, as 
demonstrated by the occurrence of lymphoproliferative disorders in those with impaired T-
cell responses.  (Rickinson, A.B., Kieff, E., 2007. Epstein-Barr virus. In: Knipe, D.M), Field’s 
Virology. Lippincott Williams & Wilkins, Philadelphia, pp. 2575–2627).  
Low numbers of EBV specific CD4+ T-cells are a risk factor for EBV associated disease in 
patients treated with immunosuppressive medication [129].  Anti-EBV T-cell responses are 
primarily directed against EBNA3A, LMP2 and EBNA1, with frequencies of up to 1% of 
CD8+ T-cells [84].  Lytic responses reach up to 3% of peripheral CD8+ T-cells, and typically 
target BZLF1 and BRLF1. Anti-EBV responses are considerable smaller than HCMV specific 
responses [135] [129]. 
 
Peptide stimulation of CD4+ and CD8+ T-cells by their respective HCMV peptide targets can 
result in the production of IFN and TNF.  CD4+ T-cells can also be stimulated using a 
mixture generated by lysing HCMV infected fibroblasts.  This method requires the presence 
of antigen presenting cells, which take up the antigen, process it, and present it to CD4+ T-
cells.  Peptide stimulation involves peptides, which activate T-cells, without the requirement 
for processing by APCs. 
T-cell responses are thought to be more important than humoral responses for control of 
herpesviruses [128].  T-cells detect intracellular pathogen, by the presentation of viral 
antigens on infected cell surfaces, and are therefore much more efficient at controlling virus.  
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Results 
 
 
Figure 4: Percentage of CD3+ CD4+ T-cells producing IFN in response to stimulation 
with; A, HCMV infected lysed human fibroblasts (control n=14, SLE n=22), B, three 
HCMV peptide mixes (control n=14, SLE n=15).  Only HCMV seropositive individuals 
have been included.  Bars represent mean ± SEM. 
 
A similar proportion of CD3+ CD4+ PBMCs from SLE patients and healthy controls produce 
IFN in response to in-vitro stimulation with HCMV lysate or HCMV peptide pools (Figure 
4).  Absolute numbers of CD3+ CD4+ T-cells are not known for controls so can not be 
compared directly with those of SLE patients.  However, absolute numbers of HCMV specific 
CD3+ CD4+ cells are likely to be lower, as 38.1% of SLE patients measured here were 
lymphopenic (<1 x 10
9
/L), and median lymphocyte count was 1x10
9
/L. cell  Generally, 
patients and controls with negative IgG responses do not produce IFN in response to HCMV 
lysate stimulation.  Mean IFN production on response to HCMV lysate in sero-negatives was 
0.013% and 0.005% in controls and SLE patients respectively, compared to 1.095% and 
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1.096% of sero-positives. Similar results were found on stimulation with HCMV peptide 
mixes.  Six of 24 seropositive SLE patients, capable of producing IFN in response to HCMV 
peptide stimulation, did not produce any IFN on stimulation with HCMV lysate.  All of 20 
healthy sero-positive controls tested were able to produce IFN on stimulation with HCMV 
lysate (p=0.0161 by χ2).  There was no association between ability to produce IFN in 
response to HCMV lysate and treatment by any specific drug, or with disease activity.  In 
both SLE patients and healthy controls, the percentage of CD3+ CD4+ cells producing IFN 
is lower in response to peptide stimulation than HCMV lysate stimulation.  The frequency of 
IFN response to HCMV lysate was similar in seronegative SLE patients and seronegative 
controls ( mean ± SE, 0.019±0.013 vs. 0.013±0.007 respectively, p=0.04808). 
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Figure 5:  Proportion of CD3+ CD8+ T-cells producing IFN in response to stimulation 
with A, HCMV peptide pools (control n=16, SLE n=17) and B, EBV peptide pools (control 
n=24, SLE n=34).  Only seropositive patients and controls have been included for each 
virus. Bars represent mean ± SEM. 
 
A similar proportion of CD3+CD8+ T-cells produce IFN in response to ex-vivo stimulation 
with HCMV peptide mixes in vitro in SLE patients and controls (Figure 5).  As with CD3+ 
CD4+ T-cells, absolute numbers of cells responding to HCMV in vivo is likely to be lower in 
SLE patients, due to lymphopenia.  SLE patients have an increased frequency of CD3+ CD8+ 
T-cells responding to EBV lytic peptides by producing IFN (0.4820% ±0.09873 versus 
0.09980% ±0.03461 respectively, mean ± SEM. p=0.01).  There is no difference in the 
frequency of cells producing IFN in response to latency peptides (p=0.8636).  SLE patients 
have significantly more CD3+ CD8+ cells producing IFN in response to lytic peptides, than 
to latency peptides (p=0.0023).  This is not the case in controls (p=0.3963). 
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Figure 6: Proportion of CD4+ and CD8+ cells producing IFN in response to stimulation 
with SEB (control n=14, SLE n=35). 
 
There is no difference between the proportion of CD4+ or CD8+ T-cells producing IFN in 
response to SEB stimulation (Figure 6).  Neither are there any differences in the percentages 
of individuals able to generate a response to SEB.  
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Figure 7:  Expression of differentiation markers on T-cell pool. Cells were analysed after 
18 hours incubation in 5% FCS RPMI with no stimulation.  The proportion of CD4+ or 
CD8+cells expressing CD28, CD27 and CD57 differentiation markers is shown.  SLE 
patients and healthy controls have been grouped based on HCMV seropositivity.  Bars 
represent mean ± SEM.  Statistics are shown in table 7.  Control CMV- n=12, control 
CMV+ n=23, SLE CMV- n=25, SLE CMV+ n=24. 
 
 
 
 
 
 
 
 
  84 
 
 
 
 
 
                    
    CD4+    CD8+  
  
Populations 
compared 
Bars 
compared 
 
CD27+ 
 
CD28+ CD57+   CD27+ CD28+ 
 
CD57+ 
Control CMV+ vs CMV- 1 vs. 2 ** ns ***  *** ns *** 
SLE CMV+ vs CMV- 3 vs. 4 *** * **   **  ns *** 
CMV - Control vs SLE 1 vs. 3 ns ns *  ns ns ns 
CMV+ Control vs SLE 2 vs. 4 ns ns ns   ns ns ns 
          
 
Table 7: Significance of data shown in figure 7 by Mann-Whitney.  *** represents p<0.001, 
** represents p<0.01, * represents p<0.05.   
 
 
 
 
                
  SLE Control 
  
  Correlation 
Linear 
regression 
r
2
 Correlation 
Linear 
regression 
r
2
 
CD28 
4+ 0.0446* 0.073 0.0866 0.0084* 0.0303* 0.1561 
8+ 0.5069 0.4566 0.0155 0.0001* 0.0001* 0.4915 
CD27 
4+ 0.1323 0.6941 0.0031 0.0001* 0.0021* 0.2743 
8+ 0.0011* 0.0004* 0.2229 0.0001* 0.0001* 0.4627 
CD57 
4+ 0.075 0.7444 0.0022 0.0002* 0.0223* 0.1621 
8+ 0.0029* 0.0016* 0.1881 0.0001* 0.0001* 0.3954 
        
Table 8:  The association between the expression of phenotypic markers and age of 
participants. Correlation by spearman's rank, and p value and r
2 
of linear regression are 
shown. 
 
 
There were no differences in the percentage of CD4+ or CD8+ T-cells expressing CD27, 
CD28 or CD57 between SLE patients and healthy controls when entire populations are 
examined (data not shown p=ns).  Seropositivity in both controls and SLE patients is 
associated with a reduction in percentage of T cells expressing CD27, and an increase in 
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surface expression of CD57 on CD4+ and CD8+ T-cells (Figure 7 and Table 7).  There is also 
significantly lower expression of CD28 in HCMV positive SLE patients compared to HCMV 
negative SLE patients.  Among HCMV positive individuals, there is no difference in 
expression of any of the markers frequencies between controls and SLE patients.   Among 
HCMV negative individuals, SLE patients have significantly higher expression of CD57 on 
CD4+ cells, than controls.  HCMV has a marked effect on the expression of CD27 and CD57 
on T-cells from controls and SLE patients.  SLE patients' overall immune repertoire is very 
similar to that of controls, and is similarly affected by CMV seropositivity. 
There was a trend towards SLE patents having a lower CD4+ to CD8+ (i.e. fewer CD4+ cells 
per CD8+ cells) ratio compared to controls but the result did not reach significance 
(p=0.0563).  There were no significant differences in CD4+ CD8+ ratio between younger and 
older patients and controls.   Furthermore, an inverted CD4+ CD8+ ratio was not associated 
with any alterations in disease activity (p=0.51). 
There is enormous variation in expression of the phenotypic markers considered, on both 
CD4+ and CD8+ cells, among SLE patients and controls.  These variations were strongly 
associated with the age of the participant among controls. Among controls, in CD4+ and 
CD8+ T-cells there are correlations between CD28, CD27 and CD57 expression and age 
(Table 8).  There are also significant associations by linear regression among controls with 
expression of these phenotypic markers.  The relationship between age and expression of 
these markers is less clear among SLE patients.     
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Figure 8a:  Percentage of CD4+ T-cells expressing CD28, CD27 and CD57 differentiation 
markers on stimulation with HCMV lysate.   Percentage expression on total CD4+ cell pool 
and on CD4+ cells producing IFN.  Production of IFN was in response to 18hstimulation 
with HCMV infected, lysed fibroblasts.  Only individuals producing IFN in response to 
CMV lysate have been included.  Bars represent mean values ± SEM. Kruskal-Wallis 
analysis and Dunn 
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Figure 8b:  Percentage of CD8+ T-cells expressing CD28, CD27 and CD57 differentiation 
markers.   Percentage expression on CD8+ cells and on CD8+ cells producing IFN.  
Production of IFN was in response to 18h stimulation with HCMV IE-1, and pp65 peptide 
mixes.  Bars represent mean values. Kruskal-Wallis analysis and Dunns 
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Figure 8c:  Percentage of CD8+ T-cells expressing CD28, CD27 and CD57 differentiation 
markers.   Percentage expression on CD8+ cells and on CD8+ cells producing IFN.  
Production of IFN was in response to 18h stimulation with EBV lytic and latent peptide 
mixes.  Bars represent mean values. Kruskal-Wallis analysis and Dunns 
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CD4+ T-cells producing IFN in response to HCMV lysate have reduced surface expression 
of CD28 and CD27, and increased surface expression of CD57 compared to the total CD4+ 
T-cell population (Figure 8a).  This is true in SLE patients and healthy controls and the degree 
of reduction/ increase is similar in SLE patients and controls. 
 
As with CD4+ T-cells, HCMV specific cells express lower levels of surface CD27.  CMV 
specific CD8+ cells also express lower levels of CD28 and increased levels of CD57, 
although this does not reach significance for all examples (Figure 8b).  There are no other 
significant differences in expression of these surface markers between SLE patients and 
healthy controls, nor any significant differences in expression levels between cells responding 
to IE-1 or pp65, although there is a trend towards cells responding to IE-1 having a more 
differentiated phenotype than those responding to pp65, as determined by expression levels of 
CD27, CD28 and CD57. 
 
CD8+ T-cells producing IFN in response to EBV peptide pools have reduced expression of 
CD27 (Figure 8c), but no significant reduction in surface expression of CD28. CD57 
expression on CD8+ T-cells responding to EBV lytic peptide is significantly higher for SLE 
patients than healthy controls (Figure 8c, p=0.0264).  CD57 expression is also higher on 
CD8+ cells from SLE patients than controls.  These are the only differences between 
expression of these markers between SLE patients and controls.  The phenotypic alterations 
associated with CMV specificity are of much greater magnitude than those associated with 
EBV seropositivity, especially the alterations in CD28 expression.    
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Fig 9: Association between cells IFN production and IgG titre in controls (n=19) and SLE  
patients (n=28).  The proportion of CD4+ T-cells producing IFN in response to 18h 
stimulation with HCMV infected, lysed fibroblasts compared to anti-HCMV IgG titre. Only 
HCMV seropositive individuals have been included. Correlation by Spearman's rank 
 
 
 
There is a significant correlation between anti-HCMV IgG titre and the percentage of cells 
producing IFN in response to stimulation with HCMV lysate (Figure 9), in controls and SLE 
patients (p=0.0431 and 0.0004 respectively, Spearman's rank) 
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Figure 10: Percentage of CD8+ T-cells binding to tetramer. Cells from seropositive 
individuals were stained with tetramers appropriate to their HLA type.  Results for cells 
stained individually have been pooled to give a total percentage of cells responding in each 
individual.  Bars represent mean ± SEM. 
 
 
 
 
There is no difference in the percentage of CD8+ T-cells specific for the HCMV or EBV 
peptides tested (Figure 10). There is however a trend towards higher frequencies of T-cells 
responding to HCMV in SLE patients than controls. 
 
  93 
 
 
 
 
Figure 11:  Expression of differentiation markers T-cells.  The proportion of CD4+ or 
CD8+ cells expressing CD28, CD27 and CD57 differentiation markers.  PBMC were stored 
in liquid nitrogen for up to 1 year, defrosted and then analysed.  SLE patients and healthy 
controls have been grouped based on HCMV seropositivity.  Bars represent mean ± SEM.  
Control CMV - n=7, control CMV + n=10, SLE CMV- n=23, SLE CMV+ n=16. 
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    CD4+    CD8+  
  
Populations 
compared 
Bars 
compared 
 
CD27+ 
 
CD28+ CD57+   CD27+ CD28+ 
 
CD57+ 
Control CMV+ vs CMV- 1 vs. 2 ns ns *  *** * *** 
SLE CMV+ vs CMV- 3 vs. 4 * ns **   **  * *** 
CMV - Control vs SLE 1 vs. 3 ns ns ns  ns ns ns 
CMV+ Control vs SLE 2 vs. 4 * ns ns   ns ns ns 
          
 
          
Table 9: Significance of data shown in figure 11 by Mann-Whitney.  *** represents 
p<0.001, ** represents p<0.01, * represents p<0.05.   
 
 
Phenotypic analysis of CD4+ and CD8+ cells that have previously been frozen (Figure 8), 
gives different results to analysis using fresh cells incubated overnight in 10% FCS (Figure 
11, Table 9).  In cells that have been previously frozen the most profound effects are 
noticeable in the CD8+ T-cell pool.  Here, in common with results from fresh cells, CMV 
seropositivity is associated with a reduction in surface expression of CD28 and an increase in 
expression of CD57, in SLE patients and controls.  In addition, frozen cells show a significant 
reduction in expression of CD28 on CD8+ cells from HCMV seropositive SLE patients and 
controls.  In the CD8+ pool there are no differences in surface expression of any of the 
markers used between SLE patients and controls.  CD4+ T-cells show a CMV associated 
increase in CD57 expression in SLE patients and controls, but no reduction on CD28 
expression.  CD27 expression is higher amongst HCMV positive SLE patients than controls, 
but is still expressed at reduced level compared to CMV+ SLE patients. 
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Figure 12:  Association between percentage of cell binding tetramer and IgG titre in SLE 
patients. Only seropositive SLE patients have been included.  P value represents 
Spearman's rank. 
 
There is a significant positive correlation between anti-HCMV IgG titre and the proportion of 
CD8+ T-cells binding to tetramer in SLE patients (Figure 12).  No such association exists for 
anti-EBV response.  It was not possible to analyse similar data for healthy controls, as 
insufficient numbers were available. 
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Discussion 
IFN responses to EBV lytic peptides are elevated in SLE patients 
Frequency of CD8+ T-cells responding to EBV lytic peptides is elevated in SLE patients 
compared to controls, this may indicate more frequent experience of lytic peptides caused by 
more frequent virus reactivation.  Responses are not elevated in response to latency peptides; 
therefore the increase is specific for lytic peptides. 
Elevated frequencies of CD8+ cells responding to EBV have also been found in patients with 
rheumatoid arthritis, following stimulation with a mixture of lytic and latency peptides [127].   
Percentages of T-cells producing IFN in response to peptide are lower than those generated 
in response to HCMV lysate as HCMV lysate contains all HCMV peptides.  The peptide 
mixes are a limited set of peptides, which are in turn restricted by a limited set of HLA types, 
which the tested individual may, or may not possess. 
The percentage of CD8+T-cells responding to stimulation with the third peptide mix is very 
low as only one CD8 specific peptide is included in the pool.  The proportion of CD4+ T-cells 
responding to HCMV peptide stimulation is lower than the proportion of CD8+ cells 
responding.  This may be due to the CD8+ T-cells being more important in defence against 
HCMV, but it may also reflect the lower proportion of CD4 specific epitopes available. 
The proportion of CD3+ CD8+ T-cells specific for CMV is greater that those specific for 
EBV, as measured by IFN production.  This indicates that HCMV requires a greater degree 
of immune control than EBV. 
It was not possible in this study to directly compare the frequencies of HCMV specific CD4+ 
and CD8+ T-cells.  Gamadia et al showed that functional CD8+ T-cells, as determined by 
ability to produce IFN, correlates with functional CD4+ responses in healthy controls.  This 
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suggests both CD4+ and CD8+ responses are controlled by the same factors, and that both are 
crucial in virus management [133]. 
 
IFN production is impaired in a subset of SLE patients 
It is more common for HCMV seropositive SLE patients to not produce IFN in response to 
HCMV lysate stimulation.  Six SLE patients are unable to produce IFN in response to lysate 
but do in response to HCMV or EBV peptide.  SLE patients' PBMCs also respond to SEB at a 
similar frequency to control and produce a similar sized response.  They are therefore capable 
of IFN production on appropriate stimulation, but are not producing it in response to HCMV 
lysate.  HCMV lysate stimulation differs from peptide stimulation in that it requires 
processing by antigen presenting cells.  As T-cells are stimulated with lysate in the presence 
of autologous APCs within the PBMC mix, it is possible that APCs in these SLE patients are 
not adequately processing or presenting peptide to generate T-cell stimulation.  It is also 
possible that there is some impairment of IFN production by CD4+ T-cells, which CD8+ T-
cells do not share.  It has not been possible to identify any characteristics of disease, or 
treatment regimen, associated with this inability to respond to HCMV lysate, but it is 
plausible that this impairment is due to treatment. 
The quantity of IFN produced per responsive cell was not recorded; it is possible that SLE 
patients have reduced intensity of IFN production per cell, compared to controls. 
Frequency of IFN producing HCMV specific CD8+ T-cells is elevated in corticosteroid 
treated patients who have undergone kidney transplant [133]. 
The lack of elevated IFN production in response to HCMV lysate by HCMV seronegative 
SLE patients, compared to seronegative controls, suggests that CD4+ T-cells are not 
responding to the self antigens in the stimulation mix. 
  98 
Tetramer responses do not correlate with IFN production 
The elevated anti-EBV IgG and elevated IFN production in response to EBV peptide would 
suggest that both humoral and cellular responses to EBV are exaggerated in SLE patients.  
However, the proportion of T-cells binding tetramer is not elevated.  The lack of any 
significant differences may be de to the restricted numbers of patients and controls tested, and 
the limited panel of tetramers used.  As tetramers are specific for particular HLA restricted 
peptides, they are not necessarily representative of the magnitude or specificity of the entire 
T-cell response.   
 
Cell surface differentiation markers are similar in SLE and controls 
There is no difference in the percentage of CD4+ or CD8+ T-cells expressing the 
differentiation markers CD28, CD27 and CD57, between SLE patients and healthy controls.  
Using this limited method of assessing the differentiation status of cells, it appears that the 
overall immune repertoire is similar in SLE and healthy controls[136].  The degree to which 
HCMV infection alters the expression of surface markers associated with differentiation 
status, is similar in SLE patients and healthy controls.  This suggests HCMV has a similar 
immunomodulatory capacity in SLE patients as controls.  CD4+ CD28- T-cells have been 
associated with HCMV infection in SLE previously [43]. 
CD57 expression is elevated on unfrozen un-stimulated CD8+ T-cells.  CD57 is a known 
marker of antigen experience, being up-regulated on antigen stimulation.  It is plausible that 
the inflammatory environment and excessive antigenic stimulation in SLE causes increased 
expression of this molecule on the T-cell pool.  T-cells producing IFN in response to IE-1 
stimulation also have increased expression of CD57 compared to controls, this may be due to 
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normal up-regulation in response to HCMV infection in combination with the increased 
background expression found in SLE patients. 
Phenotyping of T-cell pools using unfrozen cells incubated for 16 hours gave different results 
to when cells that had been previously frozen were used.  On previously frozen cells only 
CD8+ T-cells showed phenotypic changes associated with CMV infection.  It is impossible to 
know with this data whether cells that have been frozen immediately after isolation, or cells 
that have been cultured overnight, give the most accurate representation of in-vivo phenotype, 
or whether CD4+ or CD8+ cells are being modified to a greater extent.  The most accurate in-
vitro method would be to examine cells immediately after separation, but even this method 
cannot accurately recreate the conditions a peripheral PBMC experiences in vivo. 
The expression of differentiation markers on CMV and EBV specific cells in healthy people 
has been widely studied, with similar results to those found here.  What has not been shown 
before however, is the expression level of differentiation markers of HCMV and EBV specific 
cells in SLE patients.  PBMCs show very similar modifications in differentiation marker 
expression in SLE as in normal individuals, suggesting they have similar responses to, and 
similar effects of, herpesvirus infection. 
 
It is worth considering the variation in level of surface expression of CD28, CD27 and CD57.  
Even in individuals with no known immune dysfunction there is huge variation in expression 
level.  The variation in expression is most likely due to the large variation in age of 
participants.  The correlation between loss of CD28 and CD27, and gain of CD57 with age, is 
less clear in SLE patients than controls.  A study by Du et al, found that in healthy controls, 
TREC frequency correlated with age in healthy controls but not in SLE patients[40].  Both 
phenotyping and quantification of TRECs can be considered markers of previous stimulation, 
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both indicate there is no accumulation of cells, which have undergone increasing stimulation 
with age.  Other previous work has shown that the decline of CD8+ CD28 expression is 
already present in younger SLE patients, and is not dependant on age [43].  This may be due 
to younger SLE patients having already undergone significant levels of stimulation.  The 
maintenance of expression of these markers in older SLE patients may also reflect the reduced 
seroconversion of patients, compared to controls. 
The association between CD28 expression and the other characteristics investigated, is less 
powerful that the associations with CD27 and CD57.  This may be related to the reduced 
numbers of controls and SLE patients' PBMCs stained with this antibody. 
 
 
T-cell IFN production correlates with IgG titre 
 The correlation in SLE patients and controls between anti-CMV IgG titre and frequency of 
T-cell responses to CMV indicate that both branches of the immune system are co-ordinated 
in their function.  It is possible that like IgG titre, anti-CMV T-cell responses accumulate with 
age, and may reflect time since infection. 
It has been shown previously that magnitude of CD8+ response does not correlate with the 
frequency of anti HCMV IgG antibodies.  However, the same study showed that the diversity 
of the T-cell response, as measured by V usage, is inversely correlated with anti-HCMV IgG 
titre. This suggests the diversity, not the magnitude is responsible for virus control, and that 
those with large clonal expansions, and theoretically large viral loads, also have large humoral 
responses. 
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Results 3: EBV load 
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Introduction 
EBV load varies enormously between healthy individuals.  Load is 500x to 1000x higher 
during acute infection than in long term carriage, and high load in IM is associated with more 
severe symptoms [129].  Elevated EBV loads are also found in cases of asymptomatic 
primary infection, at similar levels to those in symptomatic infection.  Cases of asymptomatic 
infection are, by their very nature, rarely identified, so it not known how commonly this 
occurs [129].  Post-IM, and presumably post asymptomatic infection, EBV load in blood 
reduces with a half-life of 1.5 days for the first 2 weeks, then more slowly after this date [94].  
Reduction in load in the oropharynx, as demonstrated by continued virus shedding, takes 
considerably longer [129].   
EBV load will be examined with reference to anti-EBV responses in controls and SLE 
patients. It has previously been reported that EBV load is 40x higher in SLE patients than in 
healthy controls, so this will be examined in relation to humoral and cellular responses. 
In healthy controls, periods of EBV reactivation are associated with periods of reduced 
frequency of anti-EBV CD8+ responses [89], implying T-cell frequency or function is 
responsible for EBV control.  Decline of EBV load post IM is also accompanied by an 
increase in frequency of anti-EBV CD8+ T-cells.  Number of EBV specific T-cells also 
correlates with rate of reduction in EBV load [94].   
CMV/EBV interaction 
There is evidence to suggest that HCMV infection can have effects on the immune response 
to EBV infection in healthy controls.  In HCMV negative, EBV positive individuals, anti-
EBV T cell responses increase with age, in those also carrying HCMV there is no such 
increase [129].   
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EBV load correlates with HCMV load in bronchoalveolar lavage samples from patients post 
lung-transplant, suggesting factors controlling increase in load for one virus, also have an 
impact on the load of the other[129].  Experimentally, superinfection of EBV positive cell 
lines results in EBV reactivation [129]. 
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Results 
 
 
 
Figure 13: EBV load.  Copies of virus genome per million PBMC in controls (n=37) and 
SLE patients (n=51).  Bars represent mean ± SEM.  Only EBV+ individuals are 
represented. 
 
EBV+ SLE patients have significantly higher viral loads than controls, with mean loads of 
952.9 and 174.8 copies of virus genome per million PMC respectively (Figure 13).  SLE 
patients are also more likely to have a detectable virus load, with 16 of 38 positive controls 
having a detectable load and 34 of 51 positive SLE patients having detectable load 
(p=0.0209χ2).  Increased detectable load overall is caused by an increase in detectable load in 
the younger population.  More SLE patients under the age of 43 have a detectable load than 
controls under the age of 43 (p=0.0091 χ2).  There is no difference in the frequency of virus 
detection between older SLE patients and older controls.  Nine controls with no detectable 
load had detectable serological responses. 16 SLE patients with no detectable EBV load were 
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seropositive by anti-EBNA-1 ELISA anti-VCA IFA (p=ns).  There was a trend towards 
seropositive controls with undetectable load being younger than seropositive controls with 
detectable load but it did not reach significance (p=0.082).   
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Figure 14: Association between EBV load and age.  Each point represents an individual's 
EBV load per million PBMC, and their age at first donation.  All controls (n=25) and SLE 
patients (n=58) have been included. 
 
To determine whether the reduced detection of EBV genome in younger controls was due to 
load being below detection threshold or due to reduced prevalence we examined the 
correlation between age and EBV load.  Among the control population, there is a correlation 
between age, and copies of virus genome per million PBMC (Figure 14 p=0.0160 Spearman's 
rank).  No such correlation exists in SLE patients (p=0.9210).  There is also a correlation 
between virus load per B-cell and age in controls (data not shown p=0.004), there is no such 
association in SLE patients, nor is there an association between age and virus load per ml of 
blood.  There is no difference in EBV load between males and females (data not shown). 
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Figure 15: Association between EBV load and the number of cells specific for lytic and 
latent peptide mixes in SLE patients.  Both frequency (n=41) and absolute numbers (n=40) 
of cells are shown.  Specificity is determined by the production of IFN in response to 
stimulation with each peptide.  Correlation by spearman's rank. 
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There is a negative correlation between the percentage of CD8+ T-cells producing IFN in 
response to lytic peptide mixes, and the viral load per million PBMC in SLE patients (Figure 
15 p=0.0034).  No similar correlation occurs in healthy controls, although numbers are 
limited.  There is also a negative correlation between absolute numbers of CD8+ T-cells 
responding to lytic peptides and absolute viral load, no such association for latent responses 
exists (p=0.0072 vs p=0.1292 respectively).  Among healthy controls there is a trend towards 
a negative correlation between EBV load and percentage of cells producing IFN in response 
to latency peptides (p=0.0611), but not lytic peptide (p=0.4727).  
There is no correlation between anti-EBNA-1 IgG titre and viral load in SLE patients or 
healthy controls.  There is also no association between anti-EBV IgM titre and EBV load. 
 
 
 
 
 
 
Figure 16: Association between EBV load and tetramer responses.  Each point represents 
EBV genome copies per million PBMC and the percentage of CD8+ T-cells binding to 
tetramer.  The first donation of SLE patients only is represented.  Patients with values of 0 
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will not appear on the graph due to the scale but have been included in p value 
calculations. 
 
There is no correlation between frequency or absolute number of tetramer responses and EBV 
load, in SLE patients or healthy controls (Figure 16). 
 
 
 
 
Figure 17: EBV load in HCMV+ and HCMV- groups.  Controls and SLE patients were 
divided into HCMV+ and HCMV- categories.  EBV load is shown as copies of virus 
genome per million PBMC.  Bars represent mean ± SEM.  Control CMV- n=11, control 
CMV+ n=18, SLE CMV- n=21, SLE CMV+ n=25. 
 
There is a significant difference in the viral load of SLE patients, compared to controls, but 
this difference is limited to those who are HCMV seropositive (Figure 17).  There is no 
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difference in EBV load of HCMV positive and negative controls, or HCMV positive or 
negative SLE patients. 
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Discussion 
EBV load is elevated in SLE patients 
The increased frequency of detection of virus in younger SLE patients is probably due to 
increased virus load.  Younger controls, who are sero-positive and have therefore encountered 
the virus, do not have a high enough viral load for detection.  A more sensitive technique for 
detection of virus in PBMC would be useful.  It is also possible that SLE patients acquire the 
virus at a younger age than controls, allowing an accumulation of the virus with age as shown 
in figure 14.  It has been previously demonstrated that EBV is higher in SLE patients by up to 
40 fold.  A seven-fold increase in EBV load in PBMC has also been detected in patients with 
rheumatoid arthritis [127]. 
It is worth noting that EBV load is not as sensitive a test as immunofluorescence or ELISA.   
EBV load may be elevated in SLE patients due to more frequent viral reactivation.   HCMV 
and EBV are also reactivated in the synovial fluid of patients with rheumatoid arthritis [129]. 
 
If the relationship between EBV and the human immune system were representative of all 
herpesviruses, HCMV may have a similar relationship with its hosts.  Accumulation of virus 
load over time could explain the increase in HCMV specific immune responses.  Were the 
virus to accumulate over time in any given individual, EBV load could be used as a marker of 
time since infection.  Unfortunately it has not been possible to determine HCMV load in SLE 
patients or controls.  It could be predicted that, like EBV, HCMV load would be higher in 
SLE patients, and inversely correlated with the proportion of immune repertoire devoted to its 
control. 
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EBV load is inversely correlated with CD8+ T-cell responses in SLE patients 
Elevated EBV loads are found in SLE patients with low frequencies and numbers of CD8+ 
EBV specific T-cells.  This suggests reduced T-cell control allows an increase in EBV load.  
The same correlation does not occur in controls as SLE patients, indicating this is not a 
universal phenomenon, but a result of impaired T-cell responses.  However, fewer controls 
were assessed than SLE patients, and there was a trend towards an inverse correlation 
between EBV and latent peptide responses in controls. 
The lack of any correlation between EBV load and tetramer positive cell frequency is likely 
due to tetramers only recognising a very restricted panel of antigen specificities.  Indeed, there 
was also no correlation between tetramer frequency and frequency of cells producing IFN in 
response to stimulation.  A further factor may be the reduced numbers of patients and controls 
samples analysed using tetramers. 
A small study in 2011 of 16 older adults found that those with detectable HCMV load, by 
nested PCR from monocytes, had significantly higher frequencies of pp65 specific CD8+ T-
cells, but found no association between virus detection and IgG responses[137].  Among 
rheumatoid arthritis patients, EBV load was positively correlated with frequency of CD8+ 
EBV specific T-cells  [127]. 
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EBV load is not associated with current antibody responses 
There is no such correlation between EBV load and current anti-EBV EBNA-1 IgG, 
suggesting that this response is not impaired in SLE. Either IgG is not vital in the control of 
replication, or IgG and EBV load are measuring different aspects of the host/virus 
relationship.   Anti-EBNA-1 IgG response reflects the current state of immune challenge EBV 
represents.  As such, if the challenge is not currently elevated in SLE, the IgG titre will not be 
elevated.  However, EBV load represents years of accumulation of virus, and as such may 
represent the lifetimes immunological challenge the virus has represented.   
Anti-EBNA-1 antibodies have also been shown to bind dsDNA, so it is possible that anti-
dsDNA antibodies are altering the results, and hiding any association.  There is no correlation 
between anti-EBNA-1 IgG and EBV load in controls, but this population is smaller.  
Furthermore, when patients with the highest level of anti-dsDNA binding were excluded, 
there was still no correlation between EBV load and anti-EBNA- IgG (p=0.1712 data not 
shown). 
 
EBV load is only elevated in CMV positive SLE patients 
HCMV seropositivity does not affect EBV load in controls, suggesting the immuno-
modulatory activities of HCMV do not affect host ability to control EBV in healthy 
individuals.  
The elevated EBV load found in SLE patients is limited to CMV positive individuals.  This 
suggests HCMV may have some contributing effect to the elevation in load.  However, 
among SLE patients, EBV load is not significantly higher in CMV positives, as would be 
expected if HCMV were responsible for the increased load. 
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Results 4: Clinical Associations 
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Introduction 
One of the most important issues regarding the relationship between herpes viruses and SLE, 
is whether these viruses have any effect on disease activity.  Were they found to have a role in 
exacerbation of disease; it may be clinically useful to give antiviral medication.  Primary 
infection or periodic reactivation of viruses could, in theory cause an exacerbation of disease 
by provoking non-specific or bystander immune responses against self, or specific responses 
caused by molecular mimicry.  Conversely, SLE and it's associated immune suppression due 
to disease activity and treatment, could impair the ability of the immune system to control the 
viruses, resulting in more frequent reactivations.  
This chapter will consider the effects HCMV and EBV seropositivity have on disease activity, 
and other parameters used clinically, to measure disease severity.  Current disease activity is 
measured in this study using the BILAG scoring system [50].  A damage index is used to 
reflect the severity of past disease activity.  CRP levels are examined as a measure or 
systemic inflammation.  C3 and C4 levels also give clues to current disease activity by 
showing how much of these complement proteins have been used up in immune responses.  A 
drop in complement level therefore indicates an increase in disease activity.  An increase in 
anti-dsDNA IgG titre is predictive of flare.   
The stability of IgG response to HCMV, and EBV load in SLE patients will also be examined 
longitudinally and compared to changes in disease activity or medication. 
Finally, patient characteristics such as age, sex, time since diagnosis and the age at which 
disease was diagnosed, are examined in relation to the carriage of HCMV or EBV. 
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Treatment data was collected and patients were categorised based on the drug taken at that 
visit.  Only the presence or absence of each drug was recorded, not the dose, nor any 
alterations in dose. 
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Results 
 
 
Figure 18: Age at diagnosis.  All SLE patients were categorised as HCMV negative (n=32) 
or HCMV positive (n=39).  Mean age at diagnosis is represented ± SEM. 
 
HCMV negative patients are diagnosed at a mean age of 25.56± 1.060, whereas HCMV 
positive patients are diagnosed 7 years later, at 32.13± 1.968 respectively (Figure 18).  
Conversely, those diagnosed at a younger age are less likely to be seropositive than those that 
developed the virus later.  Median age of diagnosis for all patients was 26 years, those 
diagnosed younger than this were less likely to be seropositive than those diagnosed after 26 
(p=0.0484).  100% of patients diagnosed at or older than 40 years are seropositive (n=11 
p=0.0007 when compared to prevalence among <40).  No relationship was found between 
HCMV seropositivity and the number of years since diagnosis.  There is no significant 
difference in age of HCMV positive and HCMV negative individuals (p=0.1176). 
 In healthy controls HCMV sero-positives are significantly older than seronegatives 
(p=0.0085).  There is also no difference in the age at which EBV seronegative and EBV 
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seropositive patients were diagnosed, or their age at blood donation.  There are no differences 
in clinical data between patients diagnosed younger and older than mean diagnosis age of 30.  
The youngest diagnosis was at age 14, the oldest at 61, therefore if HCMV infection is 
resulting in a delay of onset, it is of no benefit to patients once a diagnosis has been made.  
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Figure 19:  Association between seropositivity and clinical data.  A.  SLE patients were 
grouped based on HCMV (negative n=35, positive n=36) and EBV (negative n=4, positive 
n=58) seropositivity.  B.  Patients were grouped based on HCMV/EBV seropositivity and 
the presence of any damage.  Bars represent mean ± SEM. 
 
There is no association between HCMV and EBV seropositivity, detection of EBV load, or 
presence of T-cell responses, and any of the clinical parameters considered here (Figure 19).  
Furthermore, there is no association between magnitude of response to these viruses, by any 
method used, and any of the clinical parameters examined. 
There were very few incidences of activity flares in the population studied during the period 
samples were taken.  Median disease activity was one, indicating minimal activity on one 
system. Only four of 88 patients had disease activity greater than 10, and 17 had disease 
activity greater than five.  The maximum disease activity recorded was 13.  14 patients had no 
activity at all. Median CRP was 3mg/L, and the maximum recorded was 44mg/L.  Median C3 
and C4 levels were 1.05 and 0.19 respectively.  Median dsDNA titre was 30U, maximum 
recorded was 900U.  There was no difference between any of the clinical parameters 
considered in patients younger or older than the median (data not shown). 
In this data set, C3, C4, CRP and dsDNA did not correlate with current disease activity. 
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Figure 20: Disease activity and EBV load.  Patients were categorised based on having 
current disease activity of 0 or 1 (minimal/no activity, n=25)), or disease activity of 2 (n=26) 
or more (some disease activity). Disease activity and EBV load are from the same timepoint, 
only the first donation is shown for each patient.  Bars represent mean± SEM.  Points 
represent individual patients. 
 
EBV load is not associated with disease activity (Figure 20), when any cut off of disease 
activity is considered.  There is also no association between EBV load per ml of blood and 
disease activity.  Neither is there any correlation between disease activity and EBV load.  The 
magnitude of anti-HCMV and anti-EBV T-cell responses, both by IFN production and by 
tetramer binding, are not associated with disease activity, or any of the other clinical 
parameters considered.  Humoral responses to HCMV and EBV are also not associated with 
disease activity, or other disease parameters.  EBV load is also not associated with any of the 
other recorded measures of disease activity. 
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Figure 21: Azathioprine (untreated n=40, treated n=13) and Mycophenolate mofetil 
(untreated n=30, treated n=23) treatment and EBV load.  
 
Treatment of SLE patients was heterogenous, but generally consistent for each individual.  
Therefore, only treatment at first blood donation has been considered.  Most patients were 
receiving a number of different drugs.  Most patients were treated with prednisiole (92.7%), 
and hydroxycholoquinne (76.8%).  Smaller percentages were treated using azathioprine 
(28.0%) and mycophenolate mofetil (36.6%).  A small minority were treated with 
methotrexate (9.8%), cylosporin (2.4%), rituxibab (1.22%) and tacrolimus (1.22%).  
EBV load, both per PBMC and per ml blood, is elevated in patients treated with azathioprine 
(Figure 21, p=0.0286).  No other drug is associated with an increase or reduction in EBV 
load.  No treatment had any association with the presence or magnitude of T-cell responses 
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against HCMV or EBV by tetramer or IFN production.  Humoral responses against HCMV, 
EBV and tetanus were unaffected by the presence of any one drug.  
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Figure 22: EBV load and anti-HCMV IgG titre on consecutive donations.  Samples were 
taken a minimum of three months apart, and a maximum of one year apart.  Only patients 
HCMV positive at at least one donation were included. 
 
EBV load is fairly consistent over time (Figure 22).  It was not possible to associate any 
changes in load with changes in disease activity or treatment.  Healthy controls only provided 
one sample, making it impossible to compare the longitudinal variation of EBV load in SLE 
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patients, with that of healthy controls.  Anti-HCMV IgG titre shows more variability over 
time, but it was not possible to associate any changes in response with changes in disease 
activity or treatment.  Other methods of measuring anti-HCMV and EBV responses were not 
measured frequently enough to examine longitudinal changes.   
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Discussion 
Age of diagnosis 
HCMV positive patients develop disease 7 years later than seronegatives. A delay of this 
length is unlikely to be due to delayed diagnosis.  It is not known when patients acquired the 
virus, therefore it impossible to know whether HCMV seroconversion occurred before SLE 
diagnosis.  It is possible that those predisposed to develop disease later, are more likely to 
acquire the virus, or that clinically relevant SLE makes it less likely to acquire virus.  This 
hypothesis would fit with the finding that older SLE patients are less likely to be seropositive 
than age matched controls, and the finding that those diagnosed younger are less likely to 
have the virus.  Clinically relevant disease may make it harder to acquire the virus, so those 
with disease had fewer years in which they were likely to acquire it. It seems implausible that 
a fully functioning immune system is necessary for infection, as HCMV infection is generally 
only pathological in those with impaired immune function i.e. neonates and those with HIV or 
immunosuppressive medication.  However, HCMV associated pathogenesis in the 
immunosuppressed may be due to reactivation, from latency in the host or from donated 
tissue, rather than primary infection.  It has previously been shown in a cohort of Mexican 
SLE patients that those HCMV IgG positive, IgM positive developed disease younger than 
IgG positive IgM negative.  This suggests frequent virus reactivation is associated with earlier 
disease development.  However, CMV negative individuals were excluded from the study, as 
they only made up 3% of the population [129]. 
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Virus does not affect clinical outcome 
HCMV and EBV seropositivity have no discernable effect on disease activity or clinical 
parameters, therefore can not be involved in the exacerbation of disease.  Elevated EBV load, 
suggestive of impaired T-cell control also shows no association with exacerbation of disease, 
therefore virus reactivation cannot be the causative agent of SLE exacerbation.  It is not 
known whether CMV may have this effect.  Conversely, given the lack of association, it is 
unlikely that disease activity is responsible for reactivation of EBV, or any of the alterations 
in anti-viral responses. 
However, none of the recognised markers of disease activity recorded here correlate with 
disease activity as would be predicted.  This suggests the data set is not large enough to show 
such correlations.  It is also possible that the associations are not recognisable due to the 
relatively few episodes of elevated disease activity.  The majority of patients have either no 
activity at all (17%) or very minimal activity, with BILAG scores of between 1 and 4 (63%), 
indicating only mild symptoms. 
 
Treatment associations 
Azathioprine treatment is linked to elevated virus load, both per PBMC and per ml of blood, 
mycophenolate mofetil is not, and neither are any other drugs tested.  As no form of treatment 
is associated with changes in T-cell or antibody responses, the alteration in load associated 
with Azathioprine may be due to alterations in antigen processing.  Azathioprine is a purine 
analogue, it functions by inhibiting cell proliferation via interferance with DNA replication.  
Doesch et al and shubert et al showed in 2008 that EBV load post-heart transplant was 
elevated in patients treated with azathioprine. 
In CMV seronegative recipients of CMV positive kidney transplants, HCMV seroconversion 
  130 
was just as likely in those treated with mycophenolate mofetil, as those without such 
treatment.  However, incidence of HCMV related disease (ie fever, leukocytopenia, 
thrombocytopenia) was more common among those receiving the immunosuppressive 
medication, but did not affect the severity of symptoms[138]. 
Elevated EBV load may also be due to historical impairment of T-cell responses or associated 
EBV control.  
No individual medication used here, affected the ability of CD4+ or CD8+ T-cells to produce 
IFN.  This finding is similar to a recent study of the use of two immunosupressive drugs used 
in SLE, in solid organ transplant patients.  Treatment with cyclosporin A and tacrolimus in 
solid organ transplant patients significantly affects CD8+ T-cell's ability to produce IFN and 
TNF, but not their ability to reduce IFN alone [129].  Polyfunctionality of T-cells -the 
ability to produce multiple inflamatory cytokines -is more closely associated with their anti-
viral capacity, than is the production of IFN alone (pantaleo correlates of).  This means that 
T-cells in the SLE patients studied here, may well be impaired in their functionality, but not 
have impaired IFN responses. 
No individual medication affected anti-HCMV or anti-EBV responses.  Immunosuppressive 
medications are frequently associated with the reactivation of one or both viruses following 
solid organ transplant [129]. 
Cytomegalovirus is frequently reactivated in patients with ulcerative colitis, however 
infection disappears without antiviral agents[129].  All immunosuppressive drugs used in this 
study have been previously associated with the reactivation of CMV or EBV.  
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EBV load and anti-HCMV IgG titres are fairly stable 
EBV load and HCMV IgG titre are fairly stable over time, as are disease activity levels.  It 
was not possible to examine longitudinal changes in T-cell responses in SLE patients.  It is 
likely that changes anti-HCMV IgG would correlate with magnitude of T-cell response 
longitudinally, as they correlate in cross section of the population.  The alterations in load or 
anti-HCMV titre identified, were no associated with changes in disease activity or treatment. 
Unfortunately it was not possible to examine the stability of any responses in healthy controls 
as only one sample was obtained for each.  
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DISCUSSION AND CONCLUSIONS 
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EBV is not necessary for SLE development and neither virus is associated with clinical 
outcomes 
 
The identification of SLE patients without the virus also shows that EBV is not necessary for 
disease development.  Two patients, of 86, had no detectable EBV load, no anti-EBV 
antibodies and no T-cells producing IFN in response to EBV peptide stimulation.  
Furthermore, no association has been found between the carriage of either virus, or the 
response to either virus, and disease activity.  It is therefore unlikely that these two viruses are 
contributing to the etiology or exacerbation of disease.  
 
HCMV delays the development of SLE 
 
It has always been assumed that the relationship between herpesvirues and autoimmune 
diseases is likely to be a negative one.  However, in MS patients, HCMV seropositivity has 
been associated with better clinical outcome [129].  They also found that HCMV 
seropositivity is associated with later age of diagnosis, a finding that mirrors those of this 
study.  The mechanism for both may be similar, HCMV may have a protective role in 
autoimmune disease.  Unlike SLE, MS is a disease in which severity and degree of disability 
increase with age.  A later onset of disease therefore may lead to better clinical outcome in 
MS.  No association with age and clinical outcome was found in SLE patients, it was 
therefore less likely that increased age of diagnosis would improve outcome.  It is unclear 
why HCMV is associated with later onset of disease.  It may be that HCMV is more difficult 
to acquire in the autoimmune environment.  This would result in those who develop disease 
younger having lower seropositivity.  Those who develop disease later, have had more time 
with a normally functioning immune system, therefore, more time to acquire the virus, and 
have higher seropositivity. 
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CMV protects SLE patients from developing SLE early by ‘exhausting’ the supply of 
IFN. 
 
IFN is found at lower concentration in plasma of HCMV positive SLE patients.  It is 
possible that this reduction is responsible for the delay in disease development associated with 
HCMV seropositivity.  
 
PDCs in SLE patients can become unresponsive to stimulation after excessive stimulation via 
TLR9, and stop producing IFN, as their intracellular supplies of it become exhausted.  
HCMV infection causes the production of IFN, via ligation of TLR9, so it is possible that 
repeated stimulation of pDCs by HCMV has lead to their anergy, and impaired IFN 
production.  This could explain the reduced levels of IFN in HCMV positive SLE patients. 
SLE patients with elevated IFN levels also have worse disease activity.  This could also 
explain why HCMV+ SLE patients develop disease later, as their reduced plasma IFN levels 
are insufficient to allow disease initiation.  
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Anti-CMV titre and T-cell response accumulate with age 
 
Anti-HCMV responses are strongly associated with age.  This is either due to an 
accumulation of virus load as a result of multiple sub-clinical reactivations, or simply an 
accumulation of antibodies and T-cells specific for the virus.  Either way, it is possible that 
anti-HCMV response could be used as a marker of duration of infection.  EBV load also 
accumulates with age, but anti-EBV immune responses do not.  EBV load may also be 
reflective of time since infection.  It is probable that the balance between virus and host is 
different for each virus considered. SLE patients do not undergo the same alterations in anti-
virus responses, EBV load, and phenotypic changes associated with aging, as controls.  SLE 
patients' load and responses may be prematurely elevated, as a result of excessive 
reactivation, and not conducive to any further accumulation. 
 
 
 
 
SLE patients have elevated EBV loads due to immunosuppressive treatment and 
impaired T-cell responses, not due to disease. 
 
Azathioprine treatment in SLE patients is associated with a five fold increase in EBV load per 
cell.  An elevated load was also associated with reduced frequency of CD8+ T-cells 
producing IFN.  It is therefore possible that azathioprine treatment is impairing CD8 T-cell 
responses and leading to an elevation in load.  However, no association was found between 
treatment and IFN responses.  EBV load was only negatively correlated with responses to 
lytic cycle peptides, not latency peptides, suggesting impaired control of reactivation is 
responsible for elevated load.  Anti-EBV IgG titre against the latency peptide EBNA-1 was 
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also not correlated with EBV load.  Immunosupressive treatment may be affecting the time 
taken to generate a protective response in reaction to reactivation.  Raised titres of antibody 
against EBNA-1 in SLE patients may reflect increased historical reactivation, which would 
result in a larger pool of EBV specific plasma cells. 
No associations were found between any either medication and any immunological 
parameters, however, many patients are on multiple medications, making it difficult to 
identify any direct links.  Furthermore, as all patients are on some type of immunosuppressive 
agent, it is difficult to determine the effect of one drug over another.  It would be useful to 
compare EBV load and anti-herpesvirus responses in SLE patients not receiving any 
medication.  It would also be of interest to examine the effects of these drugs on herpes virus 
responses in other conditions receiving equivalent immunosuppression.  Patients receiving 
immunosuppression post-transplant are generally on much higher doses of 
immunosuppression than SLE patients, so are not directly comparable.  A more suitable 
comparison would be other conditions requiring immunosuppression such as rheumatoid 
arthritis or ulcerative colitis. 
 
Limitations 
The lack of HCMV load information is probably the greatest drawback of this work.  It is 
impossible to know whether the same relationship between T-cell response and load occurs 
for CMV as for EBV.  Another significant weakness is the lack of enough samples to show 
whether correlation exists between EBV load and anti-EBV T-cell responses in controls.  
Without this information it is not possible to know whether the inverse correlation between 
these parameters is as a result of SLE disease and treatment, or the normal relationship 
between pathogen and host. 
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It is unfortunate that full blood counts were not available for controls, as it would have been 
interesting to compare the numbers of T-cells specific for each virus, rather than just 
frequencies.  It would also have been useful, as in almost all studies, to have a greater number 
of controls, to allow better comparisons within the population.  To determine the longitudinal 
changes in healthy controls, it would have been useful to have multiple samples, to examine 
whether the changes in anti-HCMV IgG and EBV over time in SLE patients reflect changes 
in disease activity, or whether they are just normal variations within each individual. 
Historical information on patient HCMV status would have been useful, in order to discover 
whether patients were HCMV positive before disease developed.  This would clarify whether 
HCMV delays disease onset, or whether SLE patients are less likely to acquire virus.  Also, 
for all patients and controls it would be interesting to know how long ago infection occurred, 
to see whether anti-CMV IgG titre reflects time since infection. 
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Appendix 
Appendix 1.  SLE patient disease activity and treatment at recruitment. 
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1 14 f 42 d d d d d d d c 1 y y y             5 4 0.79 0.21 29 1 
2 27 f 47 d d d d d d d c 1 y y y        0 3 1.09 0.14 33 0.6 
3 25 f 45 d d d d d d c c 2 y y         y     1 3 1.04 0.21 29 0.3 
4 25 m 57 d d d d d d d c 1 y y         3 5 1.03 0.14 24 0.6 
5 32 f 53 d d d d e d c c 2   y         y     6 3 1.14 0.23 41 1.7 
6 26 m 63 d d d d d d d c 1 y y     y    3 3 0.82 0.16 27 1 
7 58 f 58 d d d d d d d b 5   y y             1 3 1.22 0.4 48 2.1 
8 29 f 49 d d d d d d d d 0 y y     y    1 3 1.29 0.18 0 1.9 
9   f   d c d d d d d c 2 y y         y     3 6 1.19 0.21 118 1 
10 42 f 62 d d d d d d e d 0 y y         8 3 1.28 0.28 21 1.5 
11 32 f 54 d d d c d d c d 2   y               2 13 1.87 0.4 0 2 
12 33 f 51 d d d c e d d d 1 y y         2 17 0.97 0.1 244 1.9 
13 18 f 37 d d d d d d c c 2 y y y             3 3 0.69 0.18 114 0.8 
14 25 f 44 d d d b d d c c 7 y y    y y    1 3 1.02 0.24 0 0.6 
15 23 f 40 d b e d d d d c 6 y y         y     0 3 1.07 0.26 23 0.9 
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16 20 f 40 d d d d e d e d 0 y y   y      0 3 0.89 0.15 0   
17 28 f 52 d d d d e d d c 1 y y y             2 3 1.41 0.25 0 1.1 
18 27 m 61 d d d c d d d c 2 y y y        1 5 1.45 0.29 0 0.9 
19 12 f 37 d c d d d d c c 3 y y y             0 13 1.4 0.2 0 2.1 
20 20 f 44 d d d d d d c c 2  y     y    3 3 0.87 0.11 28 1.1 
21 47 f 62 d d d d d d e c 1   y y             1 3 0.9 0.15 63 0.8 
22 24 f 41 d d e d d d e d 0 y  y         0 3 1.22 0.2 0 1.9 
23 34 f 51 d d d d d d d d 0 y            y     3 19 1.88 0.43 0 1.8 
24 22 f 55 d e e d d d d c 1  y         1 3 0.94 0.04 46 1.1 
25 30 f 45 d d d d e d d c 1   y               1 3 1.1 0.24 20 0.8 
26 32 f 47 c d d c d d c d 3 y  y  y         0 3 1.02 0.13 0 1.5 
27 61 m 75 d d e d d e d c 1 y  y               3 4 0.9 0.16 130 0.6 
28 33 f 47 d d d d d d c c 2 y  y   y      1 3 1.01 0.02 33 0.8 
29 31 f 42 d d d d d d d c 1 y   y       y       0 3 0.85 0.13 0 0.7 
30 19 f 34 d c d c d d c c 4 y y     y    0 3 0.98 0.14 33 1.4 
31 23 m 37 d d e d d d b c 6 y  y         y     4   0.85 0.21 39 1 
32  f 39 d d e d d d e c 1   y        1 3 1.01 0.07 0 0.9 
33 19 f 32 d d d d d e d d 0   y         y     0 3 1.4 0.17 40 3.6 
34 27 f 40 d d d d d d c c 2 y y y        0 9 1.73 0.24 0 1.1 
35 23 f 34 c c e c e b d c 9 y y               0 3 0.67 0.11 372 0.3 
36 27 f 43 d d d d d d e c 1 y   y        0 3 1.02 0.12 0 0.8 
37 35 f 46 d d e c e e e c 2 y y               1 10 1.22 0.21 62 1.1 
38 41 f 52 d d e c d d d d 1 y y     y    0 3 1.11 0.27 0 1.2 
39 18 m 37 d d d d d e e c 1 y y               4 12 1.21 0.22 0 1.7 
40 49 f 60 d d d d e d d d 0 y y     y    0 3 1.14 0.16 76 0.7 
41   f 53 d d e d e e d d 0     y             1 3 1.41 1.32 / 1.3 
42  f x d d d e e d e c 1 y y         0 3 0.92 0.16 122 1.1 
43 41 f 51 d d d d d d d c 1 y y               4 24 1.25 0.37 0 0.7 
44 20 f 28 d d e d d d c d 1  y y      y 0 4 1.06 0.19 38 1.7 
45 19 f 30 d d e d d d c c 2 y y y             0 3 0.64 0.08 197 1.1 
46 36 f 45 c c d b d d d d 7 y y     y    1 16 1.33 0.28 0 1.6 
47 38 f 49 c d d c e d c d 3   y         y     0 7 0.83 0.13 103 1.5 
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48 19 f 26 d d d d e d c c 2 y y y        0 44 1.4 0.19 0 0.4 
49 14 f 25 d c e d d d b b 11 y y           y   1 4 1.11 0.12 41 0.7 
50 34 f 40 d d e d e e d c 1 y y y        0 26 0.91 0.16 26 0.7 
51 20 f 29 d d e d e e e d 0 y                 1 3 0.86 0.19 0 2.7 
52 25 m 36 d d e d d e c c 2 y y     y    2 5 1.02 0.25 179 1 
53 41 f 47 d b c d d d e c 7 y y y             3 3 1.59 0.33 0 0.9 
54 26 f 34 d d d b e e d d 5 y y   y      0 7 1.37 0.29 211 1.6 
55 36 f 43 d e d b d d c d 6 y y         y     1 4 1.12 0.22 24 2.8 
56 39 f 46 d e d d e e c c 2  y y        0 3 1.15 0.11 62 0.5 
57 40 f 46 e e d d e d d b 5 y y         y     2 3 1.1 0.35 0 0.6 
58 21 f 26 d c e d e d c c 3 y y y        0 25 1.83 0.25 33 2.4 
59 29 f 34 d d e d e e d c 1 y y         y     1 3 1.17 0.39 42 1.1 
60 21 f 30 e d e d d d d c 1 y y     y    0 17 0.62 0.04 900 0.8 
61 20 f 24 d d e d d d d e 0 y y               0 3 1.15 0.22 0   
62 28 f 32 d d e d d e e c 1 y y         0 3 1.17 0.29 30 1.1 
63 25 f 28 d e d d d e c b 6   y         y     1 5 0.53 0.04 154 0.7 
64 23 f 26 e d e d e d d c 1 y y     y    0 3 0.72 0.15 62 0.6 
65 50 f 55 d d e d e d c b 6 y y         y     0 8 1.37 0.34 55 1.1 
66 33 f 39 d b e d e d c b 11  y     y    2 3 0.39 0.1 46 1.5 
67 23 f 29 d d e d d d d c 1 y y               0 3 0.94 0.16 0 1 
68 26 f 29 d d e d e e c d 1 y y y        0 3 1.04 0.25 0 1.6 
69 39 f 42 d d e c d e d d 1 y y         y     0 11 1.7 0.27 30 3.6 
70 24 f 25 e d d d e d d c 1 y y y        1 3 0.84 0.23 48 0.4 
71 23 f 24 c c e b d b c d 13 y y         y     0 3 1.24 0.15 0 1.9 
72 24 f 26 d c d d e d d c 2 y y   y      0 3 0.89 0.16 0 0.7 
73 25 f 26 e d e d e e d b 5         y         0 3 1.02 0.17 188 0.8 
74 57 f 57 e d e d e e c c 2 y y         0 3 0.79 0.05 129 1.4 
75 27 f 27 d d e d d e c d 1   y         y     0 3 0.89 0.24 69 2.2 
76 18 f 18 d d e d e e d d 0 y y     y    0 3 0.99 0.09 0 1.5 
77 25 f 27 e d e d d d c c 2 y y     y         0 3 1.07 0.2 100 1.2 
78 36 f 37 e a e d e e d d 12 y y   y      0 4 1.15 0.28 0 1.6 
79   f 21 d d d d d d c d 1 y y               0 3 1.16 0.15 34   
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80  f 27 d c d d d d d c 2 y y y          3 0.69 0.12 576   
81   f 22 d d d d d d d d 0   y         y     0 3 0.89 0.12 44   
82  f 43 d d d d d d d d 0  y   y      1 3 1.01 0.26 0   
83   f                                                   
84   m                                                   
 
Appendix 1:  SLE patients’ disease and treatment.  Y represents the patient is receiving the medication, dose was not considered.  Disease 
activity is scored using the BILAG system, where a represents most severe disease activity, d and e represent no current activity and never had 
activity respectively. 
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Appendix 2.   Gating strategy for intracellular staining. 
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